ciprofloxacin has been researched along with levofloxacin in 693 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.14) | 18.7374 |
| 1990's | 72 (10.39) | 18.2507 |
| 2000's | 314 (45.31) | 29.6817 |
| 2010's | 222 (32.03) | 24.3611 |
| 2020's | 84 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, H; Ohta, M | 1 |
| Dorff, PH; Perni, RB; Rake, JB; Wentland, MP | 1 |
| Frigola, J; García-Granda, S; Gómez-Gomar, A; Ortega, E; Torrens, A; Vañó, D | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Inui, K; Saito, H; Yamaguchi, H; Yano, I | 1 |
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, S; Cui, S; McDermott, PF; Meng, J; Paulsen, I; White, DG; Zhao, S | 1 |
| Bronstein, JC; Domagala, JM; Dunham, SA; Ellsworth, EL; Gage, JW; Gracheck, SJ; Hanna, DL; Huband, MD; Joannides, ET; Liu, JY; Nguyen, DQ; Sanchez, JP; Shapiro, MA; Showalter, HD; Singh, R; Stier, MA; Tran, TP; Watson, BM | 1 |
| Choi, TY; Pai, H; Seo, MR | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Catalan, A; de la Campa, AG; Dominguez, L; Escudero, JA; Gonzalez-Zorn, B; Lopez, G; Moreno, MA; Rivero, E; San Millan, A | 1 |
| Cohen, DE; Kanaya, F; Mayer, KH; Szumowski, JD | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Hashimoto, K; Hayashi, K; Ikee, Y; Nagao, Y; Nakashima, M; Sano, S; Shiro, M | 1 |
| Black, JA; Hanson, ND; Hong, SG; Hossain, A; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Barth, AL; Castanheira, M; Gales, AC; Nicoletti, AG; Pereira, AS; Pignatari, AC | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M | 1 |
| Campos, J; García-Cobos, S; Pérez-Vázquez, M; Román, F | 1 |
| Blaser, A; Case, HL; Denny, WA; Ellsworth, E; Hagen, S; Huband, M; Joannides, T; Limberakis, C; Lu, GL; Marotti, KR; Murphy, ST; Ottolini, AM; Rauckhorst, M; Rivault, F; Smaill, JB; Starr, J; Stier, M; Taylor, C; Zhu, T | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Cauda, R; Citton, R; D'Inzeo, T; Fadda, G; Fiori, B; Montuori, E; Posteraro, B; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
| Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Luzzaro, F; Mantengoli, E; Migliavacca, R; Pagani, L; Rossolini, GM; Toniolo, A | 1 |
| Cano, ME; García, I; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Clark, KP; Griffith, ME; Hawley, JS; Hospenthal, DR; Johnson, EN; Moon, JE; Murray, CK | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Chan, PK; Chau, SS; Chi, F; Ip, M; Tang, J | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J | 1 |
| Jansen, WT; Milatovic, D; Verel, A; Verhoef, J | 1 |
| Arsène, S; Leclercq, R | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Liu, Y; Shi, W; Wang, M; Wu, S; Xu, X; Ye, X; Zhang, Y | 1 |
| Chen, M; Guo, P; Sun, H; Wang, H; Xu, Y; Yang, Q; Zhu, Y | 1 |
| Brown, DL; Deziel, MR; Drusano, GL; Kulawy, RW; Liu, W; Louie, A | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Iredell, JR; Partridge, SR; Zong, Z | 1 |
| Balsalobre, L; de la Campa, AG | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Arakawa, Y; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Mataseje, L; Mulvey, MR; Nichol, K; Zhanel, GG | 1 |
| Appelbaum, PC; Ednie, LM; Hawser, S; Lociuro, S; Smith, K | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Petersen, JM; Urich, SK | 1 |
| Bethel, CR; Bonomo, RA; Carias, LL; Endimiani, A; Fox, WR; Hall, GS; Hujer, AM; Hujer, KM; Hutton, RA; Jacobs, MR; Jenkins, SG; Paterson, DL; Perez, F; Rice, LB; Tenover, FC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bonventre, EJ; Doyle, TB; Du, Q; Duncan, L; Lynch, AS; Morris, TW; Robertson, GT; Roche, ED; Yan, D | 1 |
| Benton, BM; Debabov, DV; Difuntorum, S; Krause, KM; Renelli, M; Wu, TX | 1 |
| Jia, L; Sun, H | 1 |
| Asahina, Y; Fukuda, Y; Kimura, T; Takei, M | 1 |
| Arakawa, Y; Chen, L; Chen, ZL; Deng, YT; Gao, JH; Liu, JH; Zeng, ZL | 1 |
| Carmeli, Y; Chmelnitsky, I; Navon-Venezia, S; Strahilevitz, J | 1 |
| Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 2 |
| Crabb, DM; Duffy, LB; Waites, KB | 1 |
| Baines, SD; Freeman, J; O'Connor, R; Saxton, K; Wilcox, MH | 1 |
| Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F | 1 |
| Esteban, J; Fernández-Martínez, AI; Fernández-Roblas, R; Gadea, I; García-Almeida, D; Martín-de-Hijas, NZ | 1 |
| Chen, H; Chen, M; Wang, H; Yang, H; Yang, Q | 1 |
| Amicosante, G; De Luca, F; Luzzaro, F; Migliavacca, R; Mugnaioli, C; Pagani, L; Perilli, M; Pini, B; Pollini, S; Rossolini, GM; Spalla, M; Toniolo, A | 1 |
| Becnel Boyd, L; Morgan-Linnell, SK; Steffen, D; Zechiedrich, L | 1 |
| Becnel Boyd, L; Hamill, RJ; Horton, LB; Jimenez, JR; Maynard, MJ; Morgan-Linnell, SK; Steffen, D; Sucgang, R; Versalovic, J; Zechiedrich, L | 1 |
| Bennett, JW; Herrera, ML; Jorgensen, JH; Lewis, JS; Wickes, BW | 1 |
| Chen, Z; Deng, Y; Huang, L; Liu, J; Lü, D; Ma, J; Wang, M; Wang, X; Xu, X; Zeng, Z; Zhang, Y | 1 |
| Baptista, BC; Correia, JD; da Fonseca, JD; Martínez-Martínez, L; Pomba, C | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Bell, JM; Biedenbach, DJ; Jones, RN; Sader, HS; Turnidge, JD | 1 |
| Guo, Q; Hooper, DC; Wang, M; Wang, X; Wu, S; Xu, X; Ye, X | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Bartalesi, F; Bartoloni, A; Gamboa, H; Gotuzzo, E; Mantella, A; Pallecchi, L; Riccobono, E; Rossolini, GM; Sennati, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Accogli, M; Caprioli, A; Carattoli, A; Cerquetti, M; Fortini, D; García-Fernández, A; Giufrè, M; Graziani, C; Luzzi, I | 1 |
| Hafkin, B; Hoban, DJ; Kaplan, N; Karlowsky, JA; Zhanel, GG | 1 |
| Badal, RE; Bouchillon, SK; Hawser, SP; Hoban, DJ; Hsueh, PR; Paterson, DL | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Caddick, JM; Gunell, M; Hakanen, AJ; Huovinen, P; Jalava, J; Kotilainen, P; Lilly, AJ; Piddock, LJ; Siitonen, A; Webber, MA | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Adam, HJ; Hoban, DJ; King, CR; Laing, NM; Lulashnyk, B; Zhanel, GG | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF | 1 |
| Ichiishi, S; Mikamo, H; Nakao, K; Shibata, T; Tanaka, K; Watanabe, K | 1 |
| Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O | 1 |
| Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
| Brillault, J; Couet, W; De Castro, WV | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Albertí, S; Bengoechea, JA; Doménech-Sánchez, A; Llobet, E; Martínez-Martínez, L; Padilla, E | 1 |
| Bulik, CC; Christensen, H; Nicolau, DP | 1 |
| Ahmed, S; Calderwood, SB; Faruque, AS; Hooper, DC; Jacoby, GA; Khan, WA; Kim, HB; LaRocque, RC; Park, CH; Qadri, F; Salam, MA; Wang, M | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Bartalesi, F; Bartoloni, A; Gotuzzo, E; Mantella, A; Pallecchi, L; Riccobono, E; Rossolini, GM; Sennati, S; Trigoso, C | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dunman, PM; Hood, MI; Jacobs, AC; Sayood, K; Skaar, EP | 1 |
| Bulik, CC; Crandon, JL; Kuti, JL; Nicolau, DP | 1 |
| Aquino, EE; León, CF; Otero, DM; Robledo, IE; Santana, JL; Santé, MI; Vázquez, GJ | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Chang, SC; Chen, YC; Hsia, KC; Li, SY; Liao, MH; Lin, YC; Sheng, WH | 1 |
| Blango, MG; Mulvey, MA | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
| Ardanuy, C; Brito-Avô, A; Gonçalo-Marques, J; Liñares, J; Morais, A; Pires, R; Rolo, D; Santos-Sanches, I | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Leavitt, A; Navon-Venezia, S; Ofek, I | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Badal, RE; Baquero, F; Bouchillon, SK; Cantón, R; Hawser, SP; Hoban, DJ | 1 |
| Ahn, JH; Bae, IK; Lee, JE; Lee, JJ; Lee, SH; Park, I; Park, KS; Sun, HI; Woo, GJ | 1 |
| Dal-Ré, R; García-de-Lomas, J; García-Delafuente, C; Iriarte, V; Martín-Herrero, JE; Mazón, A; Pérez-Trallero, E; Robles, P | 1 |
| Badal, RE; Bouchillon, SK; DiPersio, J; Hawser, SP; Hoban, DJ; Labombardi, VJ | 1 |
| Bai, N; Cai, Y; Li, R; Liang, B; Liu, Y; Wang, R | 1 |
| Biedenbach, DJ; Castanheira, M; Jones, RN | 1 |
| Bavari, S; Bowlin, TL; Butler, MM; Moir, DT; Panchal, RG; Peet, NP; Shinabarger, DL; Williams, JD | 1 |
| Nakaminami, H; Noguchi, N; Sasatsu, M | 1 |
| Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
| Bialek, S; Chevalier, J; Davin, A; Lavigne, JP; Leflon-Guibout, V; Marcon, E; Moreau, R; Nicolas-Chanoine, MH; Pagès, JM | 1 |
| Clark, M; Doolittle, J; Giddings, MC; Khatun, J; Ramkissoon, K; Secrest, A; Su, HC; Wolfgang, MC | 1 |
| Chan, MC; Chang, TY; Chiueh, TS; Sun, JR; Wang, WY | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
| Briales, A; Díaz de Alba, P; Domínguez-Herrera, J; Pachón, J; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Cao, J; Feng, L; Guo, H; Li, G; Liu, M; Lv, K; You, X; Zhang, Y | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F | 1 |
| Chai, Y; Guo, H; Liu, M; Sun, L; Wang, J; Yi, H; You, X | 1 |
| Azéma, J; Constant, P; Daffé, M; Guidetti, B; Kiss, R; Korolyov, A; Malet-Martino, M; Roques, C | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Anderson, BE; Burda, WN; Cormier, R; Edlinger, J; Harrington, L; Kapolka, R; Kodigepalli, KM; Roma, G; Shaw, LN; Thomas, J; Turos, E | 1 |
| Cao, J; Guo, H; Liu, M; Lv, K; Sun, Y; Wang, J; Wei, Z; Wu, J | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Basarab, GS; Bist, S; Boriack-Sjodin, PA; Dangel, B; Eakin, AE; Illingworth, R; Manchester, JI; Sherer, BA; Sriram, S; Uria-Nickelsen, M | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M | 1 |
| Basarab, GS; Brassil, P; Doig, P; Galullo, V; Gowravaram, M; Haimes, HB; Kern, G; Kutschke, A; McNulty, J; Schuck, VJ; Stone, G | 1 |
| Ference, C; Sun, S; Sun, X; Zhang, Y; Zhou, K; Zhou, N; Zhu, W | 1 |
| Deering, RW; Mincer, TJ; Poulson-Ellestad, KL; Rowley, DC; Whalen, KE | 1 |
| Bao, Y; Huang, X; Lan, S; Wang, T; Zhang, X; Zhu, S | 1 |
| Guo, H; Li, L; Liu, M; Lu, Y; Shen, W; Wang, B; Wang, M; Zhang, R; Zhang, T | 1 |
| Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J | 1 |
| Lynch, AS; Ma, Z | 1 |
| Steenbergen, J; Tanaka, SK; Villano, S | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Ashenden, S; Bender, A; Cokol, M; Karakoc, I; Kuru, N; Mason, DJ; Meral, S; Stott, I; Weinstein, ZB | 1 |
| Cvijetić, IN; Drakulić, BJ; Ernesto de Resende, P; Gibbons, S; Juranić, IO; Stapleton, P; Verbić, TŽ; Zloh, M | 1 |
| Almstead, NG; Arnold, MA; Baird, J; Branstrom, AA; Chen, G; Dumble, M; Gerasyuto, AI; Karp, GM; Narasimhan, J; Peddi, S; Prasad, JVN; Sheedy, J; Smith, S; Wang, J; Weetall, M; Woll, MG; Zhang, N; Zhang, X | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Zhang, B | 1 |
| Berry, L; Brizuela, M; Domalaon, R; Schweizer, F; Zhanel, GG | 1 |
| Bera, S; Mondal, D | 1 |
| Gao, F; Huang, G; Xiao, J | 1 |
| Liu, H; Long, S; Rakesh, KP; Zha, GF | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Aldrich, C; Brody, S; Cushman, M; Fan, BZ; Hiasa, H; Liang, JH; Lv, W; Yang, ZY | 1 |
| Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M | 1 |
| Amada, H; Endo, M; Hitaka, K; Kamitani, M; Masuko, A; Mihara, Y; Mima, M; Ohtake, N; Sugiyama, H; Takata, I; Takeuchi, T; Tamura, Y; Tanaka-Yamamoto, N; Ushiyama, F; Wada, R | 1 |
| Chen, A; Cummings, JE; Duncan, LR; English, A; Koci, B; Li, L; Lindert, S; Lu, Y; Mann, CA; McElroy, CA; Mitton-Fry, MJ; Nolan, S; Okumu, A; Papa, JL; Ratigan, SC; Roth, B; Seffernick, JT; Slayden, RA; Vibhute, S; Wozniak, DJ; Yalowich, J | 1 |
| Akhtar, S; Ansari, MM; Ghosh, JK; Mitra, K; Pant, G; Pratap Verma, D; Saroj, J; Singh, BN; Verma, NK | 1 |
| Best, S; Blades, K; Bunt, A; Butler, HS; Charrier, C; Cooper, IR; Craighead, M; Dauncey, E; Dick, E; Finlayson, J; Kirkham, J; Lyons, A; Matthews, T; Morrison, I; Moyo, E; Newman, R; Ooi, N; Orr, D; Ratcliffe, AJ; Salisbury, AM; Savage, VJ; Smith, A; Smith, O; Stokes, NR; Walker, R | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Lohan, S; Mohammed, EHM; Parang, K; Tiwari, RK | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Geweniger, KH; Isert, D; Iyer, P; Klesel, N; Koletzki, P; Limbert, M; Markus, A; Riess, G; Schramm, H | 1 |
| Kaatz, GW; Kang, SL; McGrath, BJ; Rybak, MJ; Seo, SM | 1 |
| Jones, RN; Sutton, LD | 1 |
| Cormican, MG; Jones, RN | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Morissey, I; Smith, JT | 1 |
| Kato, M; Takayama, S; Yoshida, M | 1 |
| Parte, AC; Smith, JT | 2 |
| Cherubin, CE; Stratton, CW | 1 |
| Akahane, K; Kato, M; Takayama, S | 1 |
| Bodey, GP; Dholakia, N; Ho, DH; LeBlanc, B; Rolston, KV | 1 |
| Frei, R; Hoban, DJ; Jones, RN; Marco, F; Pignatari, AC; Yamane, N | 1 |
| Foleno, BD; Fu, KP; Lafredo, SC | 1 |
| Hayden, MK; Matushek, MG; Trenholme, GM | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 4 |
| Hayakawa, I; Hohmura, M; Hoshino, K; Ishida, H; Kitamura, A; Nishino, T; Sato, K; Tanaka, M | 1 |
| Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP | 1 |
| Conejo, MC; García, I; Pascual, A; Perea, EJ; Salvador, J | 1 |
| Domingue, G; Johnson, AP; Speller, DC; Warner, M | 1 |
| Flynn, CM; Johnson, DM; Jones, RN | 1 |
| Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK | 1 |
| Barrett, JF; Frosco, M; Goldschmidt, RM; Licata, L; Smith, CE | 1 |
| Appelbaum, PC; Bajaksouzian, S; Jacobs, MR; Visalli, MA | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 2 |
| Stewart, PS; Suci, PA; Vrany, JD | 1 |
| George, J; Morrissey, I | 1 |
| Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Vouillamoz, J | 2 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Chen, C; Danziger, LH; Martin, SJ; Pendland, SL; Schreckenberger, PC | 1 |
| Jones, RN; Pfaller, MA | 2 |
| Campbell, T; Gentry, LO; Gezon, J; Nichols, RL; Smith, JW; Sokol, P; Williams, RR | 1 |
| Bauernfeind, A | 1 |
| Arnold, B; Stout, JE; Yu, VL | 1 |
| Evans, ME; Titlow, WB | 1 |
| Barrett, MS; Jones, RN | 1 |
| Appelbaum, PC; Jacobs, MR; Lin, G; Spangler, SK | 1 |
| Jasovich, A; Neto, W; Nicodemo, AC; Robledo, JA | 1 |
| Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA | 1 |
| Andrews, JM; Wise, R | 1 |
| Alperstein, P; France, K; Isenberg, HD | 2 |
| Anjo, S; Hara, A; Nakamura, M; Sakai, M | 1 |
| Aeschlimann, JR; Dresser, LD; Kaatz, GW; Rybak, MJ | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Amaratunga, D; Barrett, JF; Fernandez, J; Frosco, M; Licata, L | 1 |
| Lacy, MK; Lu, W; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR; Xu, X | 1 |
| Peters, G; von Eiff, C | 1 |
| Dabernat, H | 1 |
| Holt, HA; MacGowan, AP; Wootton, M | 1 |
| Lister, PD; Sanders, CC | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Frémaux, A; Geslin, P; Sissia, G | 1 |
| Acar, JF; Goldstein, FW; Kitzis, MD; Miegi, M | 1 |
| Bryskier, A; Drugeon, HB; Juvin, ME | 1 |
| Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R | 1 |
| Maskell, JP; Sefton, AM; Williams, JD | 1 |
| Gootz, TD; Haskell, SL; Kaczmarek, FS; Maurice, AE; Zaniewski, RP | 1 |
| Beyer, R; Cianciotto, NP; Noskin, GA; Pestova, E; Peterson, LR | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Aeschlimann, JR; Kaatz, GW; Rybak, MJ | 1 |
| Caldelari, I; Entenza, JM; Glauser, MP; Moreillon, P | 1 |
| Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Gilbert, D; Simmons, K; Zinner, SH | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| Amicosante, G; Franceschini, N; Marchetti, F; Perilli, M; Segatore, B; Setacci, D | 1 |
| Chiba, A; Harada, S; Hasegawa, M; Kaneko, A; Kobayashi, I; Koyama, H; Matsuzaki, K; Omika, K; Sasaki, J; Sato, Y | 1 |
| Maru, C; Mori, K; Takasuna, K | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Funato, T; Hongo, T; Igari, J; Iinuma, Y; Ishigo, S; Ishii, K; Ishii, M; Itoh, C; Iwata, M; Kaimori, M; Kaku, M; Kamihira, S; Kanda, M; Kashitani, F; Katoh, J; Kawahara, S; Kawamura, C; Kudoh, M; Kuwabara, M; Matsudou, Y; Matsushima, T; Miyashita, N; Miyazaki, S; Miyazaki, Y; Murakami, N; Nakagawa, K; Nakasone, I; Negayama, K; Niki, Y; Nisawataira, T; Oguri, T; Okada, J; Ono, J; Saito, Y; Sato, N; Taira, M; Takada, T; Takii, M; Tamaki, I; Tashiro, H; Tazawa, Y; Toyoshima, S; Tsujio, Y; Uehara, N; Ueno, K; Watanabe, N; Yamaguchi, K; Yamanaka, K; Yasujima, M; Yoshida, T | 1 |
| Demasters, TA; Madaras-Kelly, KJ | 1 |
| Trissel, LA; Williams, KY; Xu, QA; Zhang, Y | 1 |
| Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
| Bravos, PD; Frenkel, B; Holtom, PD; Patzakis, MJ; Pavkovic, SA; Shepherd, LE | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Dworkin, RJ; Gilbert, DN; Grunkemeier, G; Kohlhepp, SJ; Leggett, JE; Lewis, G; Slama, KA; Slaughter, SE | 1 |
| Hedges, AJ; MacGowan, AP; Sunderland, J; Tobin, CM; White, LO | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Climent, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Danziger, LH; Gotfried, MH; Rodvold, KA | 1 |
| Sato, K; Tanaka, M; Wada, K | 1 |
| Graves, A; Henry, M; Hwang, DG; O'Brien, TP; Trousdale, MD; Van Buskirk, A | 1 |
| Johnson, AP; Livermore, DM; Warner, M | 1 |
| Kawahara, S; Nagare, H; Tada, A | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Appelbaum, PC; Davies, T; Edlund, C; El Amin, N; Oh, H | 1 |
| Ball, P | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Mombelli, B; Nicola, L; Valli, M | 1 |
| Jones, ME; Karlowsky, JA; Nealy, L; Sahm, DF; Thornsberry, C | 1 |
| Milkovich, G | 1 |
| Bonfiglio, G; Cafiso, V; Campanile, F; Messina, C; Santagati, M; Stefani, S | 1 |
| Abraham, E; Fish, DN; Malone, RS; Teitelbaum, I | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Goldwater, SH; Lindgren, B; Milkovich, G; Morrison, AJ | 1 |
| Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK | 1 |
| Kushner, JM; Peckman, HJ; Snyder, CR | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Piddock, LJ; Ricci, V | 1 |
| Arias-Puente, A; Carrasco-Font, C; Fresnadillo-Martinez, MJ; García-Sáenz, MC | 1 |
| Beach, ML; Jones, RN; Pfaller, MA | 1 |
| Frothingham, R | 2 |
| Bouchillon, SK; Butler, DL; Hoban, DJ; Johnson, JL; Miller, LA; Poupard, JA; Zhanel, GG | 1 |
| Bahar, IH; Baskin, H; Doğan, Y; Yuluğ, N | 1 |
| Jung, R; Messick, CR; Pendland, SL | 1 |
| Evans, ME | 1 |
| Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Barrett, JF; Frosco, M; Ho, H; Lawrence, LE; Mazzucco, CE; Ryan, BM; Warr, G | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Anderlik, P; Lengyel, J; Máthé, A; Rókusz, L; Rozgonyi, F; Szabó, D | 1 |
| Gillespie, T; Masterton, RG | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Bosso, JA; Enzweiler, KA; Friedrich, LV; Hoban, D; Wagner, D; White, RL | 1 |
| Schaeffer, AJ | 1 |
| Catamo, G; D'Antonio, D; D'Ercole, S; Di Bonaventura, G; Piccolomini, R | 1 |
| Burgess, DS; Nathisuwan, S | 1 |
| Lister, PD | 2 |
| Erdem, I; Goktas, P; Kaya, B; Kaynar-Tascioglu, J | 1 |
| Frisbee-Hume, S; Ho, DH; LeBlanc, BM; Rolston, KV; Streeter, H | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Cambourieu, C; Nourry, H; Pouzaud, F; Rat, P; Warnet, JM | 1 |
| Castellano, G; Morillasa, JD; Pérez Carreras, M; Solís, JA; Tomás, ME | 1 |
| Cavallero, A; Gesu, GP; Marchetti, F; Piccoli, L | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yoshimori, K | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Esposito, S; Ianniello, F; Leone, S; Noviello, S | 2 |
| Abels, R; Chien, S; Goodman, DB; Hunt, TL; Natarajan, J; Noel, GJ | 1 |
| Cetin, CB; Cosar, G; Dinç, G; Ermertcan, S; Limoncu, MH | 1 |
| Boulanger, BR; Fogarty, C; Fowler, C; Kahn, JB; Morgan, N; Oross, M; Tennenberg, A; West, M; Wiesinger, B; Wu, SC | 1 |
| Aguilar, L; García-Calvo, G; García-Olmos, M; Giménez, MJ; Parra, A; Ponte, C; Soriano, F | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T | 1 |
| Doganay, M; Esel, D; Sumerkan, B | 1 |
| Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
| Carter, O; Counts, C; Dodson, S; Lody, C; Madhusudhan, KT; Ojha, N | 1 |
| Garrison, MW | 2 |
| Fraschini, F; Mattina, R; Mouton, JW; Scaglione, F | 1 |
| Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N | 1 |
| Piddock, L; Ricci, V | 1 |
| Ono, C; Tanaka, M | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Almer, LS; Balli, DJ; Beyer, JM; Cai, Y; Flamm, RK; Hensey-Rudloff, D; Nilius, AM; Shen, LL | 1 |
| Cars, O; Löwdin, E; Odenholt, I | 1 |
| Ebisu, H; Fukuda, H; Kishii, R; Takei, M | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Hakim, MA; O'Brien, TP; Reviglio, VE; Song, JK | 1 |
| Bhavnani, SM; Callen, WA; Collins, DA; Forrest, A; Gilliland, KK; Paladino, JA; Schentag, JJ | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Colin, J; Geldsetzer, K; Ropo, A; Simonpoli, S | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Li, JL; Ma, XC; Tu, ZH; Xin, J; Zhang, T | 1 |
| Bucci, FA | 1 |
| Colombo, A; De Vecchi, E; Drago, L; Gismondo, MR; Guerra, A; Medaglia, M; Nicola, L; Tocalli, L | 1 |
| Aracil, B; Campos, J; Cantón, R; Pérez-Vázquez, M; Román, F | 1 |
| Alfonso, EC; Marangon, FB; Miller, D; Muallem, MS; Romano, AC | 1 |
| Elliott, MA; Patel, R; Prabhu, RM | 1 |
| Acharya, B; Arakawa, S; Gotoh, A; Hinata, N; Kamidono, S; Kawabata, M; Kinoshita, S; Kofuku, T; Okada, H; Shigemura, K; Shirakawa, T | 1 |
| Coban, AY; Durupinar, B; Ekinci, B | 1 |
| Chow, C; Davis, E; Dunn, S; Hardten, D; Healy, DP; Holland, EJ; Lindstrom, RL; Nordlund, ML | 1 |
| Alfonso, EC; Miller, D | 1 |
| Iwashima, A; Kiguchi, T; Sato, K; Yamaguchi, M | 1 |
| Armitstead, JA; Empey, KL; Evans, ME; Martin, C; Ofotokum, I; Rapp, RP | 1 |
| Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M | 1 |
| Schito, AM; Schito, GC | 1 |
| Naber, KG | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Graninger, W; Zeitlinger, M | 1 |
| Bagnardi, V; Botteri, E; Carobbio, A; Corrao, G; Falcone, C; Leoni, O; Zambon, A | 1 |
| El-Brashy, AM; El-Sayed Metwally, M; El-Sepai, FA | 1 |
| Drlica, K; Li, X; Mariano, N; Rahal, JJ; Urban, CM | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Beekmann, SE; Doern, GV; Heilmann, KP; Miller, NJ; Rice, CL; Richter, SS | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Lister, PD; Wolter, DJ | 1 |
| Kollef, MH; Shorr, AF; Susla, GB | 1 |
| Blatun, LA; Iakovlev, VP; Svetukhin, AM; Ukhin, SA | 1 |
| Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Bauer, LA; Black, DJ; Garrison, J; Hooton, TM; Lill, JS; Raisys, VA | 1 |
| Clarke, L; Elborn, JS; Goldsmith, CE; McCaughan, J; McKnight, AJ; Millar, BC; Moore, JE; Reid, A; Shaw, A | 1 |
| Alferova, IV; Firsov, AA; Lubenko, IY; Portnoy, YA; Smirnova, MV; Zinner, SH | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Fuller, JD; Low, DE | 1 |
| Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L | 1 |
| Squire, SB; Vizel, AA; Ziganshina, LE | 1 |
| Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
| Coll, P; Mirelis, B; Miró, E; Navarro, F; Rebollo, M; Rivera, A; Sánchez, F | 1 |
| Graff, JM; Kesler-Diaz, A; McDonnell, PJ; Osann, KE; Reiser, BJ; Sarayba, MA; Shamie, N; Sweet, PM; Taban, M | 1 |
| Bhusal, Y; Shiohira, CM; Yamane, N | 1 |
| Ben-Zvi, Z; Holcberg, G; Katz, M; Polachek, H; Polachek, J; Sapir, G; Tsadkin-Tamir, M | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Jung, HC; Kim, JM; Kim, JS; Kim, N; Song, IS | 1 |
| Borrás-Blasco, J; Conesa-García, V; Gomez-Corrons, A; González-Delgado, M; Marín-Jiménez, F; Navarro-Ruiz, A | 1 |
| Kenton, I; McKinnon, PS; Mohr, JF; Okhuysen, PC; Peymann, PJ; Septimus, E | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Hikida, M; Kariyama, R; Kato, Y; Kumon, H; Mikuniya, T; Monden, K | 1 |
| Blondeau, JM; Hansen, GT | 1 |
| Dalhoff, A; Kinzig-Schippers, M; Naber, KG; Sörgel, F; Tischmeyer, U; Wagenlehner, C; Wagenlehner, FM | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Blondeau, JM; Drlica, K; Hansen, GT; Zhao, X | 1 |
| Byrns, K; Goldner, B; Makaryus, AN; Makaryus, MN; Natarajan, U; Singer, C | 1 |
| Cox, CD; Meyerrose, GE; Peeters, MJ; Seifert, CF; Tsikouris, JP | 1 |
| Anguita-Alonso, P; Jacofsky, DJ; Osmon, DR; Patel, R; Piper, KE; Rouse, MS | 1 |
| Lück, PC; Steinert, M | 1 |
| Adebayo, SA; Olapade-Olaopa, EO | 1 |
| Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Bosso, JA; Mauldin, PD | 1 |
| Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Bengoechea, JA; Campos, MA; Morey, P | 1 |
| Coll, P; Gurguí, M; Mateo, M; Mirelis, B; Miró, E; Navarro, F; Rebollo, M; Rivera, A | 1 |
| Andreeva, I; Rafalsky, V; Rjabkova, E | 1 |
| Amarnath, SK; Joshi, S | 1 |
| Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M | 1 |
| Kinzig-Schippers, M; Naber, KG; Sörgel, F; Tischmeyer, U; Wagenlehner, C; Wagenlehner, FM | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Kinzig-Schippers, M; Naber, KG; Sörgel, F; Wagenlehner, FM; Weidner, W | 1 |
| Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| Huijgens, PC; Janssen, JJ; Leidekker, ME; Simoons-Smit, AM; Timmers, GJ; Vandenbroucke-Grauls, CM | 1 |
| Shinagawa, N; Takeyama, H; Taniguchi, M; Yura, J | 1 |
| Gualco, L; Marchese, A; Schito, AM; Schito, GC | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Ali, SH; Chandraker, A; DeCaprio, JA | 1 |
| Erkin, G; Isik, SR; Kalyoncu, AF; Karakaya, G | 1 |
| Choi, EC; Choi, JS; Joo, CK; Kim, SY; Lim, JA | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Omika, K; Sato, Y | 1 |
| Amicosante, G; Celenza, G; Larosa, M; Perilli, M; Segatore, B; Setacci, D | 1 |
| Burgess, DS; Hall, RG | 1 |
| Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J | 1 |
| Bruscas Izu, C; Mauri Llerda, JA; Medrano San Ildefonso, M | 1 |
| Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
| Fisher, A; Kahn, JB; Kaul, S; Khashab, M; Peterson, J | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Cantor, LB; Catoira, YP; Hoop, JS; Morgan, LS; Valluri, S; WuDunn, D; Yung, CW | 1 |
| Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J | 1 |
| Squire, SB; Ziganshina, LE | 1 |
| Nickel, JC; Xiang, J | 1 |
| Carroll, DG; Carroll, DN | 1 |
| Hung, PP; Lin, CF; Lin, YH; Liu, MF; Shi, ZY | 1 |
| Docobo-Pérez, F; García, I; Martínez-Martínez, L; Pachón, J; Pachón-Ibañez, ME; Pascual, A; Pichardo, C; Rodríguez-Martínez, JM | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Bai, XQ; Deng, SJ; Li, L; Li, R; Liang, QF; Luo, SY; Sun, XG; Wang, ZQ | 1 |
| Abrahamian, FM; Krishnadasan, A; Moran, GJ; Stamm, WE; Talan, DA | 1 |
| Ge, DT; Ho, YY; Kong, SK; Law, PY | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ | 1 |
| García-Rodríguez, JA; Lázaro, FG; Muñoz-Bellido, JL; Rodríguez-Tarazona, RE | 1 |
| López, JM; Noguera, O; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Calenda, M; Franco, M; García, C; Passerini de Rossi, B; Vay, C | 1 |
| Basuino, L; Chambers, HF; Tattevin, P | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Allen, GP; Hankins, CD | 1 |
| Carmona, IT; Diz Dios, P; Limeres Posse, J; Núñez Otero, V | 1 |
| Ermertcan, S; Hosgor-Limoncu, M; Tasli, H; Yurtman, AN | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Abuzeid, WM; Chiu, AG; Doghramji, L; Edelstein, PH; Guss, J | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Eames, T; Grabein, B; Kroth, J; Wollenberg, A | 1 |
| Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL | 1 |
| De Vecchi, E; Drago, L; Mattina, R; Nicola, L | 1 |
| Hiraoka, R; Nakazawa, K; Shinozaki, K; Suzuki, Y; Takeshita, K; Watabe, S; Yokoyama, Y | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM | 1 |
| Finley, R; Glass, SK; McEwen, SA; Pearl, DL | 1 |
| Alves, G; Falcão, A; Fortuna, A; Lino, C; Pena, A; Sousa, J | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Chau, F; de Lastours, V; Fantin, B; Pasquet, B; Ruppé, E; Tubach, F | 1 |
| Cheow, WS; Hadinoto, K | 1 |
| Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
| Gerding, DN; Johnson, S; Nagaro, K; Phillips, ST; Sambol, SP | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Biedenbach, DJ; Farrell, DJ; Jones, RN; Liverman, LC | 1 |
| Ryzhko, IV; Trishina, AV; Verkina, LM | 1 |
| Anetseder, M; Capacchione, J; Hager, M; Metterlein, T; Muldoon, S; Roewer, N; Schuster, F; Tadda, L | 1 |
| Chamseddin, C; Jira, TH | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Bartoletti, R; Boddi, V; Cai, T; Malossini, G; Mazzoli, S; Meacci, F; Mondaini, N | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Chen, S; Hu, F; Hu, L; Li, T; Li, X; Shao, Y; Shen, J; Xiong, Z | 1 |
| Izard, D; Mullié, C; Sonnet, P | 1 |
| Di Maggio, T; Mantengoli, E; Montagnani, F; Pallecchi, L; Pollini, S; Riccobono, E; Rossolini, GM | 1 |
| Bulitta, JB; Kinzig, M; Landersdorfer, CB; Naber, CK; Naber, KG; Sauber, C; Sörgel, F; Wagenlehner, FM | 1 |
| Gao, Q; Jiang, Z; Liu, Y; Pan, B; Wang, P; Wang, T; Xie, Z | 1 |
| Ergun, H; Köseoglu-Eser, O; Mamuk, S; Melli, M; Saribas, Z | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Baquero, F; Cantón, R; Fernández-Olmos, A; García-Castillo, M; Lamas, A; Maiz, L | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Tang, HJ; Toh, HS; Wang, JH; Yu, KW | 1 |
| Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC | 1 |
| Albini, A; Fasani, E; Maraschi, F; Migliavacca, R; Nucleo, E; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Fortier, LC; Meessen-Pinard, M; Sekulovic, O | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Avison, MB; Gould, VC; Okazaki, A | 1 |
| Abriouel, H; Benomar, N; Gálvez, A; Lavilla Lerma, L; Pérez Pulido, R; Sánchez Valenzuela, A | 1 |
| Chen, X; Chen, Y; Fu, Y; Meng, F; Wang, H; Xu, H; Zhang, F; Zhang, W; Zhang, Y; Zhao, S | 1 |
| Hosono, M; Takayanagi, R; Yamada, Y; Yokoyama, H | 1 |
| Briales, A; Díaz-de-Alba, P; Docobo-Pérez, F; Domínguez-Herrera, J; López-Rojas, R; Pachón, J; Pascual, A; Pichardo, C; Rodríguez-Baño, J; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Guo, H; Li, S; Liu, M; Lu, Y; Sun, L; Wang, B; Wang, J; Wei, Z | 1 |
| Cho, JK; Kim, JH; Kim, KS | 1 |
| Albrecht, MT; Dreier, TM; Houchens, CR; Larsen, JC; Smith, AP; Stundick, MV | 1 |
| Davies, GR; Titarenko, AF; Ziganshina, LE | 1 |
| Balaji, K; Pandian, SK; Thenmozhi, R | 1 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Chang, CH; Chou, HW; Lai, MS; Lee, JJ; Shau, WY; Wang, JL | 1 |
| Budnitz, DS; Jones, SC; Mehta, H; Sorbello, A | 1 |
| Albini, A; Fasani, E; Maraschi, F; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Jiang, B; Li, Y; Qiao, SS; Qu, Y; Wang, SH; Xie, YC; Xu, CL; Zhang, JY; Zhao, Y | 1 |
| Bowlin, TL; D'Souza, S; Houseweart, C; Kim, HS; Kwasny, SM; Nguyen, ST; Nikaido, H; Opperman, TJ; Peet, NP; Walker, GC | 1 |
| Audisio, E; Busca, A; De Rosa, FG; Di Perri, G; Frairia, C; Marmont, F; Motta, I | 1 |
| Cantón, R; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Moreno-Bofarull, A; Morosini, MI; Tato, M; Vila, J | 1 |
| Klein, EY; Laxminarayan, R; May, L; Rothman, RE | 1 |
| Alshammari, TM; Caffrey, AR; LaPlante, KL; Larrat, EP; Morrill, HJ; Quilliam, BJ | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Wang, H; Zhang, FF; Zhao, CJ | 1 |
| Hollander, A; Huijbregts, MA; Oldenkamp, R; Ragas, AM | 1 |
| Kodawara, T; Masada, M; Masuda, S; Matsubara, K; Nakamura, T; Yano, Y | 1 |
| Lee, WH; Li, SA; Liu, J; Wang, YJ; Xiang, Y; Zhang, Y | 1 |
| Saito, R; Yamada, K | 1 |
| Djurdjevic, P; Ivanovic, N; Jakovljevic, I; Jelikic-Stankov, M; Joksovic, L | 1 |
| Goodwin, JS; Kuo, YF; Lin, YL; Parekh, TM; Raji, M; Tan, A | 1 |
| Cantón, R; Espinal, P; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Tato, M; Vila, J | 1 |
| Dou, M; Gong, Y; Hao, J; Sun, C | 1 |
| Deak, E; Hindler, JA; Humphries, RM; Sjölund-Karlsson, M; Skov, R; Sokovic, A | 1 |
| Ardanuy, C; Calatayud, L; de la Campa, AG; Garmendia, J; Liñares, J; Marti, S; Puig, C; Tirado-Vélez, JM; Tubau, F | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Chen, DS; Hsu, HY; Sand, D; Schur, M; She, R; Shulman, IA | 1 |
| Han, XY; Li, L; Tarrand, JJ | 1 |
| El-Shafei, A; Goldman, HB; Jones, JS; Kartha, G; Klein, EA; Unnikrishnan, R | 1 |
| Loeb, S | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Ferri, EN; Maraschi, F; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Bronk, M; Gibas, A; Matuszewski, M; Sieczkowski, M | 1 |
| Chan, S; Coulter, MM; Di Pentima, MC; Hossain, J; Rosé, L | 1 |
| Al-Salamah, T; Hayes, BD; Heil, EL; Hines, MC; Johnson, JK; Mallemat, H; Winters, ME; Witting, MD | 1 |
| Åhman, J; Kahlmeter, G; Matuschek, E; Petersen, A; Sjölund-Karlsson, M; Skov, R; Stegger, M; Torpdahl, M | 1 |
| Deak, E; Hindler, JA; Humphries, RM; Skov, R | 1 |
| Wu, L; Wu, X | 1 |
| Celia, C; Ciavarella, MT; Di Bonaventura, G; Di Marzio, L; Fiscarelli, E; Grande, R; Locatelli, M; Paolino, D; Pompilio, A; Ricciotti, G; Zengin, G | 1 |
| Beeton, ML; Chalker, VJ; Jones, LC; Maxwell, NC; Spiller, OB | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A | 1 |
| Castellanos-González, M; García-Martínez, FJ; López-Martín, I; Segurado-Rodríguez, MA | 1 |
| Aksaray, S; Avcıküçük, H; Başustaoğlu, A; Kaşkatepe, B; Süzük, S | 1 |
| Dubini, M; Marraccini, P; Pignatti, P | 1 |
| Gent, JF; Holden, PN; Kong, Y; Murphy, TF; Pettigrew, MM; Sethi, S; Tsuji, BT | 1 |
| Eraç, B; Güler, G | 1 |
| Schaeffer, EM | 1 |
| Grillon, A; Jehl, F; Kleinberg, M; Schramm, F | 1 |
| Chang, CM; Huang, CC; Ko, WC; Lee, CC; Lee, NY; Shih, HI; Tang, HJ; Wang, LR | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Das, A; Mandal, J; Natarajan, M | 1 |
| Chmura, A; Ciszek, M; Dobrzaniecka, K; Durlik, M; Kwiatkowski, A; Mlynarczyk, A; Mlynarczyk, G; Paczek, L; Sawicka-Grzelak, A; Szymanek-Majchrzak, K; Usarek, P | 1 |
| Jung, JA; Kaisar, N; Parvez, MM; Shin, HJ; Shin, JG | 1 |
| Gibas, A; Jacyna, J; Kaliszan, R; Markuszewski, MJ; Matuszewski, M; Sieczkowski, M; Siluk, D; Szerkus, O | 1 |
| Nakaminami, H; Nakase, K; Noguchi, N; Sakuma, Y | 1 |
| Chatzikonstantinou, M; Galani, I; Margaritis, A; Petrikkos, G; Souli, M | 1 |
| Ahn, J; Chukeatirote, E; Jo, A; Kim, J | 1 |
| Mospan, GA; Wargo, KA | 1 |
| Dalhoff, A; Schubert, S; Vente, A | 1 |
| Conigliaro, A; Grodin, L; Lee, SY; Rose, M; Sinert, R | 1 |
| Akdag Cayli, Y; Balducci, AG; Buttini, F; Montanari, S; Oner, L; Sahin, S; Vural, I | 1 |
| Abdelrady, AM; Farag, NE; Fawzy, MS; Moustafa, YM; Zaitone, SA | 1 |
| Przybylski, DJ; Reeves, DJ | 1 |
| Duan, J; Gao, Y; Geng, X; Kang, J; Li, X; Song, Y; Wang, S; Yin, D; Zhang, R; Zhang, Z | 1 |
| Tribble, DR | 1 |
| Ahn, J; Ding, T; Jung, LS | 1 |
| Copeland, V; McLaughlin, M; Trifilio, S | 1 |
| Cai, RX; Chen, C; Lu, Y; Shun-Mei, E; Yuan, H; Zeng, JM | 1 |
| Doi, SAR; Harris, PN; Naber, K; Roberts, MJ; Scott, S; Wagenlehner, FME | 1 |
| Alhabshan, RN; Mansour, TN | 1 |
| Amano, H; Hirano, T; Inoue, S; Kazamori, D; Kinoshita, T; Kuramoto, Y; Nishimura, K; Ohishi, K; Sakurai, A; Yazaki, A | 1 |
| Dong, S; Du, W; Gao, B; Sun, K; Sun, Y; Wu, J; Xu, H | 1 |
| Alfonso, EC; Gibbons, A; Miller, D; OʼBrien, TP; Palioura, S; Spierer, O | 1 |
| Fang, G; Gao, J; Gao, X; Li, J; Liu, H; Liu, X; Lu, X; Tang, Y; Wang, J | 1 |
| Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M | 1 |
| Khalifa, MO; Mansour, MA | 1 |
| Fung, CP; Lin, YT; Wang, FD; Wu, PF; Yang, TC | 1 |
| Marchant, J | 1 |
| Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Bassetti, M; Cojutti, P; Pea, F; Sartor, A; Scarparo, C | 1 |
| Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF | 1 |
| Rambaran, KA; Seifert, CF | 1 |
| Cho, Y; Park, HS | 1 |
| Ejaz, A; Ejaz, H; Javed, H; Saleem, R; Younas, S; Zafar, A | 1 |
| Furlan, JPR; Gallo, IFL; Sanchez, DG; Stehling, EG | 1 |
| Ben Salem, C; Brahim, A; Fathallah, N; Ouni, B; Slim, R | 1 |
| Ma, W; Row, KH | 2 |
| Adu, LB; Afriyie, DK; Amponsah, SK; Dzradosi, M; Manu-Ofei, F; Ohene-Manu, P | 1 |
| Campeau, SA; Hindler, JA; Humphries, RM; Shaffer, K | 1 |
| Bae, IG; Cho, OH; Choi, SH; Chong, YP; Kang, KC; Kim, DY; Kim, SH; Kim, YS; Lee, JH; Lee, MS; Lee, SO; Lee, YM; Moon, C; Park, KH; Park, SY; Ryu, BH; Woo, JH | 1 |
| Funaishi, K; Hattori, N; Katsutani, S; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Chopra, V; Conlon, A; Flanders, SA; Gandhi, T; Malani, AN; Vaughn, VM | 1 |
| Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S | 1 |
| Arnold, JR; Dierkhising, RA; Narayanan, PP; Sampathkumar, P; Thurber, KM | 1 |
| Kurz, X; McGettigan, P; Morales, D; Pacurariu, A; Pinheiro, L; Slattery, J | 1 |
| Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Hidalgo, AA; Millanao, AR; Mora, AY; Mora, GC; Saavedra, CP; Valenzuela, LM; Villagra, NA | 1 |
| Franceschini, D; Frigo, AC; Giusti, P; Lo, R; Lunardi, V; Moro, S; Pagetta, A; Stifani, S; Zusso, M | 1 |
| Ahn, J; Dawan, J; Ding, T; Kim, B; Kim, JC; Uddin, MJ | 1 |
| Dȩbowski, D; Gitlin-Domagalska, A; Gucwa, K; Milewski, S; Okońska, J; Olkiewicz, K; Ptaszyńska, N; Rolka, K; Ruczyński, J; Łȩgowska, A | 1 |
| Andremont, A; Burdet, C; Corbel, T; de Gunzburg, J; Ferreira, S; Mentré, F; Nevière, A; Pulse, M; Sablier-Gallis, F; Saint-Lu, N; Sayah-Jeanne, S; Weiss, W | 1 |
| Malnarcic, CM; McCaughan, J; Millar, BC; Moore, JE | 1 |
| Kakizaki, H; Sarbajna, T; Takahashi, Y; Vaidya, A | 1 |
| Li, GQ; Peng, SY; Tu, ZW; Wang, L; Yang, J | 1 |
| Bello, L; Caneiro, A; Gai, R; Galeano, S; Miller, A; Mosquera, R; Muxi, P; Oliver, AC; Pierri, S; Riva, E | 1 |
| Aubry, A; Bleibtreu, A; Fourniols, E; Funck-Brentano, C; Jaureguiberry, S; LLopis, B; Tissot, N; Zahr, N | 1 |
| Han, L; Ni, Y; Qu, J; Sun, J; Tao, Y; Xie, L; Xu, Y; Zhou, K | 1 |
| Cheng, JW; Fan, X; Hou, X; Kudinha, T; Liang, GW; Liu, C; Shao, DH; Su, JR; Wang, Y; Wei, M; Xiao, M; Xiong, ZJ; Xu, YC; Yang, CX; Yang, QW; Yu, SY | 1 |
| Bennett, AC; Bennett, CL; Witherspoon, BJ | 1 |
| Frassineti, GL; Monti, M; Ruscelli, S; Silimbani, P | 1 |
| Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL | 1 |
| Dębowski, D; Gitlin-Domagalska, A; Gucwa, K; Heldt, M; Lica, J; Martynow, D; Milewski, S; Olkiewicz, K; Ptaszyńska, N; Rolka, K; Serocki, M; Stupak, A; Łęgowska, A | 1 |
| He, X; Jian, L; Li, X; Wang, S; Zhao, L | 1 |
| Aboshanab, KM; Aboulwafa, MM; Ahmed, MT; Anwer, BE; Mohammed, MA | 1 |
| Duque-Yemail, J; Grau-López, L; Palma-Alvarez, RF; Perea-Ortueta, M; Ramos-Quiroga, JA; Robles-Martínez, M; Ros-Cucurull, E | 1 |
| da Silva, MAN; Lage, ALA; Marciano, AC; Martins, DCDS; Venâncio, MF | 1 |
| Beare, PA; Bloom, ME; Broeckel, RM; Flather, DP; Kendall, BL; Morris, CN; Offerdahl, DK; Scroggs, SLP | 1 |
| Cabañas, R; Domínguez-Ortega, J; Fiandor, A; González-Muñoz, M; Lluch-Bernal, M; Loli-Ausejo, D; Vílchez-Sánchez, F | 1 |
| Heard, K; Hughes, S; Moore, LSP; Mughal, N | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
| Elberry, AA; Hussein, RRS; Saad, NA; Samy Matar, H | 1 |
| Beberok, A; Boryczka, S; Marciniec, K; Wrześniok, D | 1 |
| Bucsa, C; Farcas, A; Huruba, M; Leucuta, DC; Mogosan, C; Sipos, M | 1 |
| Ahmad, I; Ejaz, H; Muzammil, S; Qamar, MU; Qureshi, R; Rasool, MH; Shafique, M | 1 |
| Kaczmarek, M; Staninski, K; Stodolny, M | 1 |
| Armstrong, S; Atkins, TP; Bailey, M; Bewley, KR; Clay, KA; Godwin, K; Hartley, MG; Norville, IH; Rayner, E; Vipond, J | 1 |
| Bridts, CH; Campillo-Davo, D; De Puysseleyr, LP; Ebo, DG; Elst, J; Faber, MA; Hagendorens, MM; Lion, E; Maurer, M; Mertens, C; Sabato, V; van der Poorten, MM; Van Gasse, AL; Van Houdt, M; Van Tendeloo, VF | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Czyrski, A | 1 |
| Dogan, A; Donmez, F | 1 |
| Li, Y; Xiang, Y; Xue, Z; Yang, Q | 1 |
| Adamowicz, J; Dąbrowski, P; Drewa, T; Fekner, Z; Kloskowski, T; Pokrywczyńska, M; Rasmus, M; Siedlecka, N; Szeliski, K; Wolska, A | 1 |
| Fox, BC; Lavey, SC; Lazzerini, G; Munson, E | 1 |
| Aden, JK; Benavides, TM; Giancola, SE | 1 |
| Al-Talhy, AM; Ali, H; Dadar, M; Elkharsawi, AR; Hamdy, MER; Neubauer, H; Tawab, AAAE; Wareth, G | 1 |
| Li, LH; Lin, YT; Liu, YF; Lu, HF; Yang, TC | 1 |
| Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Al Atbee, MYN; Jalil, MB | 1 |
| Ahmadi, F; Garg, AX; Kim, RB; Knoll, GA; Muanda, FT; Silverman, MS; Sontrop, JM; Sood, MM; Weir, MA; Yoo, E | 1 |
| Adly, ME; Khattab, RA; Nagy, YI; Ragab, YM; Shaker, RAE | 1 |
| Crawford, SB; Davis, WH; Geno, KA; Magee, MR; Monks, SM | 1 |
| Fan, X; Kang, X; Luo, S; Luo, X; Wang, G; Wei, Y; Zhao, S | 1 |
| Hu, S; Lou, Z; Shen, Y; Tu, M | 1 |
| Kiamos, A; Sands, M; Torrente, N; Verdecia, J | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| Ai, MY; Chen, BL; Chuang, HC; Huang, HW; Lee, YJ; Liu, HY; Tsao, LH; Wang, EY | 1 |
| Bartoszewicz, M; Brożyna, M; Dudek-Wicher, R; Dydak, K; Junka, A; Madziała, M; Oleksy-Wawrzyniak, M; Paleczny, J | 1 |
| Bower, WA; Bulitta, JB; Chatham-Stephens, K; Cook, R; Hendricks, K; Kennedy, JL; Mongkolrattanothai, T; Negron, ME; Person, MK; Shin, E; Yu, P | 1 |
| Gunardi, WD; Moehario, LH; Nainggolan, IM; Nathania, I; Nusatia, ACM; Tjoa, E; Yasmon, A | 1 |
| Ciric, L; Farhan, M; Mohy-U-Din, N; Sharif, F; Wahid, A | 1 |
| Bhatt, S; Chatterjee, S | 1 |
| Liu, B; Liu, X; Lu, M; Xiong, W | 1 |
| Holmes, M; Wildermuth, A | 1 |
| Abbas Tikki, K; Hayder Hasan, T; Sabah Bustani, G; Sadeq Al-Ethari, A | 1 |
| Hartung, FO; Herrmann, J; Kowalewski, KF; Kriegmair, MC; Michel, MS; Neuberger, M; Rassweiler-Seyfried, MC; Ritter, M; Weiß, C | 1 |
| Chunqing, L; Li, X; Rui, W; Ruijuan, Z; Yingjie, W | 1 |
| Li, X; Zhang, H; Zhao, L; Zou, H | 1 |
| Khan, M; Ma, K; Wan, I; Willcox, MD | 1 |
| Cheng, G; Diao, S; Jia, Z; Lu, X; Luo, J; Xin, L; Yang, M; Zeng, L; Zhang, L | 1 |
| Bartoletti, R; Cicione, A; DE Nunzio, C; Ficarra, V; Franco, A; Labella, M; Lombardo, R; Nacchia, A; Simonato, A; Trucchi, A; Tubaro, A | 1 |
| Chacko, S; Maheshwari, TK; Murdeshwar, S; Sheikh, RY | 1 |
| Aziz Abdulhassan, A; Jasim Obeed, R; Saad Latteef, N; Salih, WY | 1 |
| Chasqueira, MJ; Cruz, C; Fernandes, F; Paixão, P; Rodrigues, L; Santos, R | 1 |
| Adams, KK; Clarke, LG; Shah, S | 1 |
| Chen, G; Gao, H; Gu, J; Li, L; Ma, C; Yang, Z; Zhu, C | 1 |
| Borde, P; Meena, AK; Parmar, GS; Prasad, S | 1 |
| Chen, J; Li, Z; Liu, H; Shen, L; Wen, Y; Zhang, P; Zhao, W | 1 |
| Cheng, WH; Ho, CH; Su, PY | 1 |
| Algaidi, SH; Alghamdi, DI; Algheffari, SG; Alzahrani, RA; Hafiz, AM; Thabit, AK | 1 |
| Djang'eing'a Marini, R; Hamuli Ciza, P; Hubert, P; Lieberman, M; Ngono Mballa, R; Ravinetto, R; Sacré, PY; Waffo Tchounga, CA; Ziemons, E | 1 |
| Bouwman, H; Kümmerer, K; Kylin, H; Nantaba, F; Palm, WU; Wasswa, J | 1 |
| Artuković, M; Dorčić, G; Ikić Matijašević, M; Ikić, L; Kilić, P; Kurtov, K; Kurtov, M; Vodanović, M | 1 |
40 review(s) available for ciprofloxacin and levofloxacin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Drug Discovery; Humans; Microbial Sensitivity Tests; Molecular Conformation; Tetracyclines | 2016 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Current scenario of tetrazole hybrids for antibacterial activity.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Tetrazoles | 2019 |
Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Triazines; Viruses | 2020 |
Quinolone antibiotics.
Topics: | 2019 |
[Injectable quinolones].
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Injections, Intravenous; Levofloxacin; Ofloxacin | 2001 |
Seizures associated with fluoroquinolones.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Magnesium; Ofloxacin; Seizures; Sodium | 2001 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Streptococcus pneumoniae | 2004 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prostatitis; Quinolones; Severity of Illness Index; Treatment Outcome; Urinary Tract Infections | 2004 |
Clinical applications of levofloxacin for severe infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Epithelium; Humans; Infections; Levofloxacin; Lung; Ofloxacin | 2004 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; Meta-Analysis as Topic; Ofloxacin; Pneumonia, Bacterial; Quinolones; Randomized Controlled Trials as Topic | 2005 |
[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Ciprofloxacin; Gastrointestinal Diseases; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Skin Diseases; Skin Diseases, Bacterial; Soft Tissue Infections; Urea | 2004 |
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Failure | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Treatment Outcome | 2006 |
Quinolones for uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Female; Fluoroquinolones; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Randomized Controlled Trials as Topic | 2006 |
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciprofloxacin; Decision Making; Drug Resistance; Enterocolitis, Pseudomembranous; Gram-Positive Bacterial Infections; Humans; Leukemia; Levofloxacin; Lymphoma; Neoplasms; Neutropenia; Ofloxacin | 2006 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2008 |
Interactions between warfarin and three commonly prescribed fluoroquinolones.
Topics: Aza Compounds; Ciprofloxacin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoroquinolones; Humans; International Normalized Ratio; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Warfarin | 2008 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Mouth Diseases; Moxifloxacin; Ofloxacin; Oral Medicine; Quinolines | 2009 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Drug Administration Schedule; Humans; Injections, Intravenous; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule.
Topics: Animals; Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Ciprofloxacin; Disease Models, Animal; Drug Approval; Francisella tularensis; Government Regulation; Levofloxacin; Tularemia; United States; United States Food and Drug Administration | 2013 |
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy, Large-Core Needle; Ciprofloxacin; Fluoroquinolones; Fosfomycin; Humans; Image-Guided Biopsy; Levofloxacin; Male; Middle Aged; Prostate; Sepsis; Ultrasonography; Urinary Tract Infections | 2018 |
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.
Topics: Animals; Anti-Inflammatory Agents; Ciprofloxacin; Humans; Inflammation; Levofloxacin; Mice; Microglia; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4 | 2019 |
Quinolone-induced psychosis: an updated review.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Delirium; Humans; Levofloxacin; Ofloxacin; Psychoses, Substance-Induced; Quinolones | 2020 |
A systematic review and meta-analysis of levofloxacin and ciprofloxacin in the treatment of urinary tract infection.
Topics: Ciprofloxacin; Humans; Levofloxacin; Urinary Tract Infections | 2021 |
The perspective of antibiotic therapeutic challenges of brucellosis in the Middle East and North African countries: Current situation and therapeutic management.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Chloramphenicol; Ciprofloxacin; Doxycycline; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle East; Ruminants; Streptomycin; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacterial; Furazolidone; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Nitrofurantoin; Norfloxacin; Novobiocin; Rifampin; Vibrio cholerae; Virulence Factors | 2022 |
Bacteriological Studies of Venomous Snakebite Wounds in Hangzhou, Southeast China.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacteria; Cefazolin; Cefoxitin; Ciprofloxacin; Clavulanic Acid; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Snake Bites; Sulbactam; Venoms | 2022 |
Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; beta-Lactams; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Doxycycline; Glycopeptides; Humans; Levofloxacin; Lipopeptides; Models, Animal; Tetracyclines; United States | 2022 |
Fluoroquinolone antibiotics: Occurrence, mode of action, resistance, environmental detection, and remediation - A comprehensive review.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Ecosystem; Fluoroquinolones; Humans; Levofloxacin | 2022 |
Comparative effectiveness and safety of antibiotic prophylaxis during induction chemotherapy in children with acute leukaemia: a systematic review and meta-analysis.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Child; Ciprofloxacin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Levofloxacin | 2023 |
Is EMA warning on quinolones and fluoroquinolones really assessed? An EudraVigilance database analysis.
Topics: Ciprofloxacin; Fluoroquinolones; Levofloxacin; Quinolones; Retrospective Studies | 2023 |
32 trial(s) available for ciprofloxacin and levofloxacin
| Article | Year |
|---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Skin Diseases, Infectious; Treatment Outcome | 1997 |
A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Skin Diseases, Bacterial; Staphylococcal Infections; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome | 1998 |
Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis | 1998 |
Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Osteomyelitis; Quinolones | 2000 |
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
Topics: Adult; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cell Count; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Lung; Male; Middle Aged; Ofloxacin; Reference Values | 2001 |
Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tissue Distribution | 2001 |
Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Female; Humans; Imipenem; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Prospective Studies; Pseudomonas aeruginosa | 2003 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostatitis; Treatment Outcome | 2003 |
Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin.
Topics: Administration, Topical; Aged; Anti-Infective Agents; Aqueous Humor; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Ciprofloxacin; Cornea; Double-Blind Method; Female; Humans; Levofloxacin; Male; Ofloxacin; Ophthalmic Solutions | 2003 |
An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification.
Topics: Absorption; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aqueous Humor; Biological Availability; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Therapy, Combination; Female; Gas Chromatography-Mass Spectrometry; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Single-Blind Method | 2004 |
Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Aqueous Humor; Ciprofloxacin; Corneal Stroma; Double-Blind Method; Female; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Ofloxacin; Ophthalmic Solutions; Prospective Studies | 2004 |
Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.
Topics: Acecainide; Adult; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Ciprofloxacin; Cross-Over Studies; Drug Interactions; Female; Humans; Kidney; Levofloxacin; Male; Ofloxacin; Procainamide | 2005 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Method; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostate-Specific Antigen; Prostatitis | 2005 |
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Female; Humans; Hydrogen-Ion Concentration; Levofloxacin; Male; Middle Aged; Ofloxacin | 2006 |
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Ofloxacin; Quinolines; Statistics, Nonparametric; Torsades de Pointes | 2006 |
Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Delayed-Action Preparations; Humans; Levofloxacin; Ofloxacin; Proteus mirabilis; Staphylococcus; Urine | 2006 |
Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cross-Over Studies; Female; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Ofloxacin | 2006 |
A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteriuria; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pilot Projects; Placebos; Pyuria; Single-Blind Method; Treatment Outcome; Urinary Catheterization; Urinary Tract Infections | 2006 |
Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Humans; Levofloxacin; Male; Middle Aged; Neutropenia; Ofloxacin; Penicillin V; Treatment Outcome; Viridans Streptococci | 2007 |
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis | 2007 |
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Urinary Tract Infections | 2007 |
Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial.
Topics: Administration, Oral; Anti-Bacterial Agents; Aqueous Humor; Cataract Extraction; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Filtering Surgery; Humans; Levofloxacin; Ofloxacin; Ophthalmic Solutions; Prospective Studies; Single-Blind Method; Surgical Wound Infection | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Catheterization; Urinary Tract Infections | 2008 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination.
Topics: Adolescent; Adult; Body Fluids; Ciprofloxacin; Cross-Over Studies; Drug Combinations; Drug Interactions; Female; Humans; Levofloxacin; Male; Ofloxacin; Prostate; Semen; Seminal Vesicles; Tissue Distribution; Vagina; Young Adult | 2011 |
Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.
Topics: Adult; Anti-Bacterial Agents; Asian People; Ciprofloxacin; Escherichia coli Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostatitis; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome | 2012 |
Antibiotic prophylaxis in transarterial chemoembolization of hepatocellular carcinoma.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Carcinoma, Hepatocellular; Catheterization, Peripheral; Ceftriaxone; Chemoembolization, Therapeutic; Ciprofloxacin; Drug Administration Routes; Drug Monitoring; Egypt; Female; Humans; Levofloxacin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2018 |
Effect of ciprofloxacin vs levofloxacin on QTc-interval and dysglycemia in diabetic and non-diabetic patients.
Topics: Adult; Ciprofloxacin; Diabetes Mellitus; Fluoroquinolones; Humans; Levofloxacin; Prospective Studies | 2021 |
Effects of Catheter Tracking Management on Urinary Tract Function and Infection Rates in Patients With Spinal Cord Injury.
Topics: Anti-Bacterial Agents; Catheters; Ciprofloxacin; Gentamicins; Humans; Levofloxacin; Piperacillin; Quality of Life; Spinal Cord Injuries; Urinary Tract; Urinary Tract Infections | 2023 |
621 other study(ies) available for ciprofloxacin and levofloxacin
| Article | Year |
|---|---|
Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials.
Topics: 4-Quinolones; Anti-Infective Agents; Computer Simulation; Escherichia coli; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Molecular Structure; Receptors, Drug; Software; Structure-Activity Relationship | 1991 |
Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
Topics: Animals; Bacteroides; Chemical Phenomena; Chemistry; Ciprofloxacin; Escherichia coli; Mice; Ofloxacin; Oxazines; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus; Topoisomerase II Inhibitors | 1988 |
7-Azetidinylquinolones as antibacterial agents. 3. Synthesis, properties and structure-activity relationships of the stereoisomers containing a 7-(3-amino-2-methyl-1-azetidinyl) moiety.
Topics: Animals; Anti-Bacterial Agents; Azetidinecarboxylic Acid; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas Infections; Quinolones; Staphylococcal Infections; Stereoisomerism; Structure-Activity Relationship | 1995 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Topics: Acute Kidney Injury; Animals; Anti-Infective Agents; Antineoplastic Agents; Bile Ducts; Biological Availability; Blotting, Western; Caco-2 Cells; Ciprofloxacin; Cisplatin; Duodenum; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Piperazines; Rats; Rats, Wistar; Time Factors | 2004 |
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
Topics: Animals; Anti-Infective Agents; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Gene Targeting; Genes, Bacterial; Mutation; Salmonella Infections, Animal; Salmonella typhimurium | 2007 |
3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
Topics: Anti-Bacterial Agents; Bacteria; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Methicillin Resistance; Microbial Sensitivity Tests; Quinazolinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Quinolones | 2007 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
First characterization of fluoroquinolone resistance in Streptococcus suis.
Topics: Amino Acid Sequence; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Molecular Sequence Data; Point Mutation; RNA, Ribosomal, 16S; Sequence Alignment; Streptococcus suis | 2007 |
Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.
Topics: Adult; Ambulatory Care Facilities; Anti-Bacterial Agents; Boston; Female; HIV Infections; Humans; Male; Methicillin Resistance; Middle Aged; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane.
Topics: Anti-Bacterial Agents; Aza Compounds; Bridged Bicyclo Compounds; Crystallography, X-Ray; Indicators and Reagents; Magnetic Resonance Spectroscopy; Methicillin Resistance; Microbial Sensitivity Tests; Models, Molecular; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Topics: Drug Resistance, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Microbial Sensitivity Tests; Quinolones | 2007 |
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Conjugation, Genetic; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Integrons; Latin America; Molecular Sequence Data; Plasmids | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors | 2007 |
Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Mutation | 2007 |
The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Molecular Structure; Mutagenicity Tests; Nitriles; Rats; Structure-Activity Relationship | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Proteus mirabilis; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Humans; Italy; Microbial Sensitivity Tests | 2007 |
Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
Topics: Anti-Infective Agents; Bacterial Proteins; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli Proteins; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Plasmids | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Injections, Intraperitoneal; Leptospira interrogans; Leptospirosis; Levofloxacin; Mesocricetus; Ofloxacin; Serotyping; Survival Analysis | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Anti-Infective Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gene Transfer, Horizontal; Genotype; Humans; Microbial Sensitivity Tests; Phenotype; Phylogeny; Streptococcus; Streptococcus mitis; Streptococcus oralis; Streptococcus pneumoniae | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; Colistin; Colony Count, Microbial; Drug Combinations; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests | 2007 |
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
Topics: Anti-Infective Agents; Base Sequence; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blotting, Southern; Carbapenems; China; Chloramphenicol; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Rifampin; Sequence Analysis, DNA | 2007 |
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biological Transport; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Resistance, Multiple; Ethidium; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Reserpine; Streptococcus pneumoniae | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
RmtC 16S rRNA methyltransferase in Australia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Australia; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Drug Resistance, Bacterial; Genes, rRNA; Humans; Methyltransferases; Microbial Sensitivity Tests; Proteus Infections; Proteus mirabilis; RNA, Ribosomal, 16S | 2008 |
Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Recombination, Genetic; Streptococcus pneumoniae; Transcription, Genetic | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
Topics: Anti-Bacterial Agents; Conjugation, Genetic; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Fluoroquinolones; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Plasmids; Prevalence | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
Topics: Bacterial Proteins; beta-Lactamases; Canada; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Humans; Intensive Care Units; Microbial Sensitivity Tests | 2008 |
Antistreptococcal activity of AR-709 compared to that of other agents.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pyrimidines; Streptococcus pneumoniae; Streptococcus pyogenes; Tetrahydrofolate Dehydrogenase; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.
Topics: Anti-Bacterial Agents; Francisella tularensis; Humans; Microbial Sensitivity Tests; North America; Tularemia | 2008 |
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
Topics: Aged; Bacterial Proteins; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Quinolones; United States | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Rifamycins; RNA, Bacterial; Staphylococcus aureus; Topoisomerase II Inhibitors | 2008 |
In vitro activity of telavancin against resistant gram-positive bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.
Topics: Animals; Anti-Bacterial Agents; Benzoxazines; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2008 |
Coprevalence of plasmid-mediated quinolone resistance determinants QepA, Qnr, and AAC(6')-Ib-cr among 16S rRNA methylase RmtB-producing Escherichia coli isolates from pigs.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Methyltransferases; Plasmids; RNA, Ribosomal, 16S; Swine; Swine Diseases | 2008 |
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Genes, Bacterial; Microbial Sensitivity Tests; Plasmids; Quinolones | 2008 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2008 |
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Colony Count, Microbial; Cytotoxins; DNA Gyrase; Feces; Fluoroquinolones; Gastrointestinal Tract; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Ribotyping | 2009 |
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics | 2008 |
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Pigmentation; Species Specificity; Tigecycline | 2008 |
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
Topics: Acetyltransferases; Anti-Bacterial Agents; Bacterial Proteins; China; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Prevalence; Quinolones | 2008 |
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Data Collection; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Integrons; Italy; Molecular Epidemiology; Molecular Sequence Data | 2008 |
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Norfloxacin; Ofloxacin | 2009 |
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; United States | 2009 |
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
Topics: Anti-Bacterial Agents; beta-Lactamases; Enterobacter cloacae; Female; Humans; Liver Transplantation; Microbial Sensitivity Tests; Middle Aged; Pseudomonas putida; RNA, Ribosomal, 16S | 2009 |
High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
Topics: Acetyltransferases; Adolescent; Adult; Aged; Animals; Animals, Domestic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cambodia; Cephalosporins; China; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli Proteins; Female; Humans; Male; Mali; Microbial Sensitivity Tests; Middle Aged; Nasal Cavity; Plasmids; Quinolones; Young Adult | 2009 |
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence | 2009 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
Topics: Anti-Bacterial Agents; Asia; Drug Resistance, Bacterial; Europe; Gram-Positive Bacteria; Humans; Latin America; Microbial Sensitivity Tests; North America; Pacific Ocean; Quality Control; Teicoplanin; Vancomycin | 2009 |
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Base Sequence; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Proteus Infections; Proteus mirabilis; Quinolones; Sequence Analysis, DNA | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia.
Topics: Bacterial Proteins; Base Sequence; Bolivia; Child; Child, Preschool; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Humans; Infant; Klebsiella pneumoniae; Molecular Sequence Data; Peru; Plasmids; Polymerase Chain Reaction; Quinolones | 2009 |
Emergence of quinolone-resistant Bordetella pertussis in Japan.
Topics: Anti-Bacterial Agents; Bordetella pertussis; Child; DNA Gyrase; Fluoroquinolones; Humans; Japan; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Quinolones | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Plasmids; Poultry; Poultry Diseases; Quinolones; Salmonella enterica | 2009 |
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
Topics: Anti-Bacterial Agents; Benzofurans; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enterobacteriaceae; Enterococcus; Microbial Sensitivity Tests; Moraxella catarrhalis; Pyrones; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2009 |
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; China; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Imipenem; India; Klebsiella; Quinolones; Thailand | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Electroporation; Genotype; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Quinolones; Salmonella enterica | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 2009 |
Susceptibilities of 23 Desulfovibrio isolates from humans.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Clindamycin; Desulfovibrio; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2009 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Cystic Fibrosis; Humans; Levofloxacin; Lung Diseases; Microbial Sensitivity Tests; Ofloxacin; Sputum | 2010 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
Topics: Absorption; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport, Active; Cell Line; Cell Membrane Permeability; Cyclosporins; Diffusion; Drug Interactions; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Kinetics; Lipids; Lung | 2010 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Culture Media; Defensins; DNA, Bacterial; Drug Resistance, Bacterial; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lipopolysaccharides; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Phenotype; Plasmids; Polymyxin B; Polysaccharides; Repressor Proteins; RNA, Bacterial | 2010 |
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Young Adult | 2010 |
Transferable quinolone resistance in Vibrio cholerae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Chromosomes, Bacterial; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Quinolones; Vibrio cholerae | 2010 |
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2010 |
Characterization of small ColE-like plasmids mediating widespread dissemination of the qnrB19 gene in commensal enterobacteria.
Topics: Anti-Bacterial Agents; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotype; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Quinolones | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cations, Monovalent; Culture Media; Drug Resistance, Bacterial; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Humans; Microbial Sensitivity Tests; Oligonucleotide Array Sequence Analysis; Proteomics; Sodium Chloride; Virulence Factors | 2010 |
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2010 |
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Puerto Rico | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; beta-Lactamases; Carbapenems; Cephalosporins; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Taiwan | 2010 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistance, Bacterial; Endosomes; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Recurrence; Urinary Bladder; Urinary Tract Infections; Urothelium | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Carrier Proteins; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Molecular Epidemiology; Norfloxacin; Point Mutation; Portugal; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Plasmids; Polymerase Chain Reaction | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
Topics: Abdomen; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae | 2010 |
Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
Topics: Animals; Bacterial Proteins; Chickens; Citrobacter; Citrobacter freundii; Escherichia coli; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Quinolones; Swine | 2010 |
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
Topics: Ampicillin; Anti-Bacterial Agents; Cefotaxime; Erythromycin; Haemophilus influenzae; Lincosamides; Macrolides; Microbial Sensitivity Tests; Penicillins; Respiratory Tract Infections; Spain; Streptococcus pneumoniae; Streptococcus pyogenes; Streptogramin B | 2010 |
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Abdomen; Amikacin; beta-Lactams; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests | 2010 |
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mutation | 2010 |
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Minocycline; Neisseria meningitidis; Penicillins; Rifampin; Sulfamethoxazole; Triazoles; Trimethoprim | 2010 |
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
Topics: Anti-Bacterial Agents; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Indoles; Microbial Sensitivity Tests | 2010 |
Fluoroquinolone efflux by the plasmid-mediated multidrug efflux pump QacB variant QacBIII in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Fluoroquinolones; Membrane Transport Proteins; Plasmids; Staphylococcus aureus | 2010 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Biological Transport; Caenorhabditis elegans; Drug Resistance, Bacterial; Ertapenem; Klebsiella pneumoniae; Reverse Transcriptase Polymerase Chain Reaction; Virulence | 2010 |
The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Two-Dimensional; Methylmalonate-Semialdehyde Dehydrogenase (Acylating); Microbial Sensitivity Tests; Pseudomonas aeruginosa; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinate-Semialdehyde Dehydrogenase | 2010 |
Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Male; Membrane Transport Proteins; Middle Aged; Minocycline; Molecular Sequence Data; Mutagenesis, Insertional; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
Topics: Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2011 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2011 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
Design, synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-aminomethylpiperidin-1-yl)fluoroquinolone derivatives.
Topics: Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Imino Pyranoses; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa | 2011 |
Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacte
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Ciprofloxacin; Dimerization; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Neoplasms; Ofloxacin | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Topics: Acylation; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bartonella; Bartonella Infections; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2012 |
Synthesis and in vitro antibacterial activity of quinolone/naphthyridone derivatives containing 3-alkoxyimino-4-(methyl)aminopiperidine scaffolds.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Piperidines; Quinolones; Structure-Activity Relationship | 2013 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Bacteria; Disease Models, Animal; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Topoisomerase II Inhibitors; Urea | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship | 2014 |
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
Topics: Animals; Anti-Bacterial Agents; Barbiturates; Female; Fluoroquinolones; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Isoxazoles; Male; Mice; Pyridones; Rats, Wistar; Spiro Compounds; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
A potent antimicrobial compound isolated from Clathria cervicornis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biological Products; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porifera | 2015 |
Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.
Topics: Anti-Bacterial Agents; Benzimidazoles; Drug Resistance, Multiple; Fluorescent Dyes; Gram-Negative Bacteria; Membrane Transport Proteins; Metabolomics; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pseudoalteromonas; Pseudomonas aeruginosa; Pyrroles | 2015 |
Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Penicillin Resistance; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2015 |
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrrolidines; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2015 |
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism | 2015 |
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes | 2016 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
Topics: Anti-Bacterial Agents; Drug Interactions; Molecular Structure | 2017 |
Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
Topics: Anti-Bacterial Agents; Bacteria; Catalytic Domain; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Multiple; Humans; Hydrophobic and Hydrophilic Interactions; Keto Acids; Molecular Docking Simulation; Serum Albumin, Human; Structure-Activity Relationship | 2018 |
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Protein Conformation; Pyridines; Sepsis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae | 2018 |
Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
Topics: | 2019 |
Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.
Topics: Anti-Bacterial Agents; Azithromycin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Escherichia coli; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship | 2020 |
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transcriptional Regulator ERG; Vancomycin-Resistant Enterococci | 2020 |
Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with
Topics: Anti-Bacterial Agents; Dioxanes; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2021 |
Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities.
Topics: Animals; Antimicrobial Peptides; Antitubercular Agents; Cell Survival; Chemokines; Dose-Response Relationship, Drug; Erythrocytes; Humans; Lysine; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Stereoisomerism; Structure-Activity Relationship; THP-1 Cells | 2021 |
Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.
Topics: Animals; Anti-Bacterial Agents; DNA Gyrase; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Oxazolidinones; Structure-Activity Relationship; Topoisomerase II Inhibitors; Topoisomerase Inhibitors | 2022 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Amphiphilic cyclic peptide [W
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Gram-Negative Bacteria; Gram-Positive Bacteria; Meropenem; Microbial Sensitivity Tests; Peptides, Cyclic; Pseudomonas aeruginosa | 2022 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Pyelonephritis; Rats; Rats, Wistar; Sepsis; Stereoisomerism; Streptococcus pneumoniae | 1995 |
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Rifampin; Staphylococcus aureus; Stereoisomerism | 1994 |
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Topics: Ciprofloxacin; Diffusion; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Reproducibility of Results | 1995 |
Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.
Topics: Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Activity of 4-quinolones against Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Culture Media; Gram-Negative Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 1994 |
Effect of levofloxacin and ciprofloxacin injection on permeability of the tail vein in mice and skin microvasculature in rats.
Topics: Animals; Anti-Infective Agents; Capillary Permeability; Ciprofloxacin; Diphenhydramine; Hydrogen-Ion Concentration; Injections, Intravenous; Levofloxacin; Male; Mast Cells; Mice; Mice, Inbred BALB C; Microcirculation; Ofloxacin; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Skin; Tail; Veins | 1994 |
Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
Topics: Ciprofloxacin; Culture Media; Escherichia coli; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Stereoisomerism; Temperature | 1994 |
Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Listeriosis; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.
Topics: Acetamides; Alcohol Oxidoreductases; Animals; Ciprofloxacin; Excitatory Amino Acid Antagonists; Injections, Intravenous; Injections, Spinal; Levofloxacin; Male; Mice; Mice, Inbred Strains; Neurotransmitter Agents; Ofloxacin; Receptors, GABA; Seizures | 1993 |
Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Body Temperature; Ciprofloxacin; Levofloxacin; Ofloxacin; Staphylococcus aureus; Staphylococcus epidermidis; Temperature | 1994 |
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Neoplasms; Ofloxacin; Stereoisomerism | 1994 |
Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
Topics: Asia; Ciprofloxacin; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; South America | 1994 |
Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1993 |
Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Vancomycin | 1995 |
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Prevalence; Quality Control | 1996 |
Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Culture Media; Culture Media, Serum-Free; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Kinetics; Levofloxacin; Metals; Microbial Sensitivity Tests; Microscopy, Electron; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Urine | 1996 |
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Female; Kidney; Levofloxacin; Methicillin Resistance; Mice; Ofloxacin; Pyelonephritis; Staphylococcal Infections | 1996 |
Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cisplatin; Doxorubicin; Fluoroquinolones; Humans; Levofloxacin; Neutrophils; Ofloxacin; Paclitaxel; Quinolones; Staphylococcus aureus | 1996 |
In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; England; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae; Wales | 1996 |
In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple; Gentamicins; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperacillin; Pseudomonas aeruginosa; Tobramycin | 1996 |
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Levofloxacin; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 1996 |
Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Staphylococcus aureus; Streptococcus pneumoniae | 1997 |
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
Topics: Acinetobacter; Amikacin; Anti-Infective Agents; Ciprofloxacin; Drug Combinations; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1997 |
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Topics: Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Cats; Ciprofloxacin; Dogs; Fluoroquinolones; Haplorhini; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Swine; Wound Infection | 1997 |
Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.
Topics: Anti-Infective Agents; Biofilms; Biological Transport; Ciprofloxacin; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Spectroscopy, Fourier Transform Infrared | 1997 |
Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1997 |
The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Endocarditis, Bacterial; Floxacillin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rats; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1997 |
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteriological Techniques; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Sensitivity and Specificity; Species Specificity; Streptococcus pneumoniae | 1997 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1997 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae | 1997 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Erythromycin; HL-60 Cells; Humans; Legionella; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Reproducibility of Results | 1998 |
Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae; Time Factors | 1997 |
Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Staphylococcus aureus | 1998 |
Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Moraxella catarrhalis; Neisseriaceae; Ofloxacin; Piperazines; Time Factors | 1998 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Bites and Stings; Bites, Human; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Species Specificity; Wound Infection | 1998 |
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1998 |
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Levofloxacin; Moraxella catarrhalis; Ofloxacin; Respiratory Tract Infections; Streptococcus pneumoniae | 1998 |
In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Corynebacterium; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin | 1998 |
Comparison of the complexation of fluoroquinolone antimicrobials with metal ions by nuclear magnetic resonance spectroscopy.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Magnetic Resonance Spectroscopy; Metals; Ofloxacin; Quinolones; Solutions; Temperature | 1999 |
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
Topics: Anti-Infective Agents; Bacterial Proteins; Biological Transport; Ciprofloxacin; Drug Synergism; Humans; Levofloxacin; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Ofloxacin; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 1999 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess.
Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Female; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Staphylococcal Skin Infections | 1999 |
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Topics: Ampicillin; Ampicillin Resistance; Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Penicillins; Pneumococcal Infections | 1999 |
In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and neutropenic patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Micrococcus; Neutropenia; Ofloxacin | 1998 |
In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
Topics: Anti-Infective Agents; beta-Lactams; Burkholderia cepacia; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Pseudomonas aeruginosa; Xanthomonas | 1999 |
The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1999 |
The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 1999 |
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Dose-Response Relationship, Drug; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 1999 |
In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Pefloxacin | 1999 |
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1999 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Humans; Lethal Dose 50; Levofloxacin; Mice; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; Survival Analysis; Time Factors; Uranyl Nitrate | 1999 |
Selection of resistant variants of respiratory pathogens by quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Nalidixic Acid; Ofloxacin; Pneumonia, Bacterial; Streptococcus pneumoniae | 1999 |
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Topics: Adrenergic Uptake Inhibitors; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Reserpine; Staphylococcus aureus; Topoisomerase II Inhibitors | 1999 |
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Phenotype; Streptococcus pneumoniae; Transformation, Bacterial | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
Topics: Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Multidrug Resistance-Associated Proteins; Norfloxacin; Ofloxacin; Omeprazole; Species Specificity; Staphylococcal Infections; Staphylococcus aureus | 1999 |
Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
Topics: Animals; Anti-Infective Agents; Catheterization; Ceftriaxone; Ciprofloxacin; Endocarditis, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin Resistance; Rats; Streptococcal Infections; Streptococcus; Streptococcus sanguis; Treatment Outcome | 1999 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Humans; Levofloxacin; Ofloxacin; Streptococcus pneumoniae | 2000 |
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Topics: Anti-Infective Agents; Catalysis; Ciprofloxacin; DNA; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Naphthyridines; Ofloxacin; Staphylococcus aureus; Topoisomerase II Inhibitors | 2000 |
Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2000 |
[In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Topics: Ampicillin; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefaclor; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Humans; Levofloxacin; Methicillin; Ofloxacin; Penicillin G; Penicillin Resistance; Penicillins | 1999 |
Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dogs; Female; Histamine Release; Levofloxacin; Male; Mast Cells; Ofloxacin; Rats; Rats, Sprague-Dawley; Species Specificity | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
[Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Respiratory Tract Infections; Urinary Tract Infections | 2000 |
In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Levofloxacin; Logistic Models; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Streptococcus pneumoniae | 2000 |
Compatibility and stability of linezolid injection admixed with three quinolone antibiotics.
Topics: Acetamides; Anti-Infective Agents; Ciprofloxacin; Drug Stability; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro.
Topics: Animals; Anti-Infective Agents; Bromodeoxyuridine; Calcification, Physiologic; Cell Count; Cell Division; Cells, Cultured; Ciprofloxacin; Dose-Response Relationship, Drug; Extracellular Matrix; Fluoroquinolones; Levofloxacin; Mice; Naphthyridines; Ofloxacin; Osteoblasts | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Phenotype; Pseudomonas aeruginosa; Regression Analysis; Reproducibility of Results; Staphylococcus aureus | 2001 |
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
Topics: Anti-Infective Agents; Aza Compounds; Biological Assay; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Klebsiella; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Photochemistry; Quinolines | 2001 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain | 2001 |
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Colony Count, Microbial; Conjunctivitis, Bacterial; Drug Evaluation; Drug Resistance, Microbial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Mycobacterium; Mycobacterium fortuitum; Mycobacterium kansasii; Mycobacterium tuberculosis; Ofloxacin | 2001 |
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Topics: Anti-Infective Agents; Ciprofloxacin; Databases, Factual; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Pseudomonas aeruginosa | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Topics: Amino Acid Substitution; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2001 |
Safety of the new fluoroquinolones compared with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines | 2000 |
Activity of levofloxacin and ciprofloxacin against urinary pathogens.
Topics: Anti-Infective Agents; Bacterial Adhesion; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Urinary Tract Infections | 2001 |
Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Pneumococcal Infections; Population Surveillance; Streptococcus pneumoniae | 2001 |
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Topics: Administration, Oral; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Utilization; Female; Hospitalization; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Virginia | 2001 |
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
Topics: Anti-Infective Agents; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Levofloxacin; Methicillin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Staphylococcus | 2001 |
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Renal Insufficiency; Renal Replacement Therapy | 2001 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Comparison of therapeutic interchange with standard educational tools for influencing fluoroquinolone prescribing.
Topics: Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Cost Control; Cost Savings; Drug Costs; Drug Utilization; Female; Hospital Bed Capacity; Humans; Levofloxacin; Male; Ofloxacin; Pharmacy Service, Hospital; Practice Patterns, Physicians'; Statistics, Nonparametric; Therapeutic Equivalency; Treatment Outcome; Virginia | 2001 |
An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Eye Infections, Bacterial; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Retrospective Studies; Staphylococcus aureus; Time Factors | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolines | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Gatifloxacin; Humans; Lactams; Latin America; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Regional Medical Programs; Urinary Tract Infections | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Europe; Fluoroquinolones; Gemifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin | 2001 |
Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli.
Topics: Anti-Infective Agents; Bacterial Adhesion; Cell Line; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Female; Hemagglutination; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Urinary Tract Infections | 2002 |
In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Synergism; Humans; Lactams; Levofloxacin; Microbial Sensitivity Tests; Monobactams; Ofloxacin; Penicillins; Piperacillin; Pseudomonas aeruginosa | 2002 |
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Streptococcus pneumoniae | 2001 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Penicillins; Quinolines; Streptococcal Infections; Streptococcus | 2001 |
Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Blood Bactericidal Activity; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Indoles; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Sensitivity and Specificity; Staphylococcus aureus | 2002 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
Topics: Animals; Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Ofloxacin | 2002 |
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic; Time Factors | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2002 |
Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Staphylococcus aureus; Stenotrophomonas maltophilia | 2002 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Sensitivity and Specificity; Streptococcus pneumoniae | 2002 |
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2002 |
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Sensitivity and Specificity | 2002 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France; Humans; Levofloxacin; Long QT Syndrome; Ofloxacin; Pneumonia | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[Tenotoxic potential of fluoroquinolones in the choice of surgical antibiotic prophylaxis in ophthalmology].
Topics: Achilles Tendon; Aged; Animals; Antibiotic Prophylaxis; Cells, Cultured; Ciprofloxacin; Data Interpretation, Statistical; Fluoroquinolones; Free Radicals; Humans; Levofloxacin; Middle Aged; Ofloxacin; Ophthalmologic Surgical Procedures; Pefloxacin; Rabbits; Rupture; Tendons; Time Factors | 2002 |
[Rupture of the Achilles' tendon secondary to levofloxacin].
Topics: Achilles Tendon; Adult; Ceftriaxone; Ciprofloxacin; Crohn Disease; Drug Therapy, Combination; Humans; Intestinal Perforation; Levofloxacin; Male; Methylprednisolone; Metronidazole; Ofloxacin; Rupture; Tendinopathy | 2003 |
Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2003 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprofloxacin; Dosage Forms; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Macrolides; Ofloxacin; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors; Urinary Tract Infections | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
[Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
Topics: Anti-Infective Agents; Ciprofloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Urinary Tract Infections | 2002 |
Emergence of phenotypic resistance to ciprofloxacin and levofloxacin in methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains.
Topics: Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Phenotype; Serial Passage; Staphylococcus aureus | 2003 |
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Guinea Pigs; Levofloxacin; Lung; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Levofloxacin; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2003 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin G; Penicillins; Turkey | 2003 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Humans; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2003 |
Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Protein Binding; Streptococcus pneumoniae; Survival Analysis | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Blood Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Protein Binding; Quinolones; Rats | 2003 |
Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Area Under Curve; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Theoretical; Ofloxacin; Streptococcus pneumoniae | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Blotting, Western; Ciprofloxacin; Cornea; Debridement; Female; Immunoenzyme Techniques; Levofloxacin; Matrix Metalloproteinases; Ofloxacin; Ophthalmic Solutions; Rats; Rats, Inbred Lew | 2003 |
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.
Topics: Anti-Bacterial Agents; Benchmarking; Ciprofloxacin; Drug Costs; Drug Resistance, Bacterial; Economics, Hospital; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; United States | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Endocarditis, Bacterial; Floxacillin; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rats; Staphylococcal Infections; Streptococcal Infections; Vancomycin; Viridans Streptococci | 2004 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Compare two methods of measuring DNA damage induced by photogenotoxicity of fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Comet Assay; Cricetinae; Cricetulus; DNA; DNA Damage; Fibroblasts; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Ultraviolet Rays | 2004 |
[Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002].
Topics: Body Fluids; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2003 |
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
Topics: Aza Compounds; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Ofloxacin; Polymerase Chain Reaction; Quinolines | 2004 |
Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Conjunctivitis, Bacterial; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Keratitis; Levofloxacin; Methicillin; Microbial Sensitivity Tests; Ofloxacin; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure | 2004 |
Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gonorrhea; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin | 2004 |
A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.
Topics: Bacterial Outer Membrane Proteins; Ciprofloxacin; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2004 |
Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Endophthalmitis; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae; Viridans Streptococci | 2004 |
[Isolation-frequency and antibiotic susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa isolated in regional core hospitals in the Nagaoka district of Niigata Prefecture (changes for 3 years)].
Topics: Anti-Infective Agents; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Haemophilus influenzae; Hospitals, Urban; Humans; Japan; Levofloxacin; Ofloxacin; Penicillin G; Pseudomonas aeruginosa; Streptococcus pneumoniae; Time Factors | 2004 |
Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cost Savings; Drug Costs; Fluoroquinolones; Formularies, Hospital as Topic; Hospital Costs; Hospitals, University; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Organizational Policy | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Staphylococcal Infections | 2004 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Levofloxacin; Lung; Mice; Mice, Inbred CBA; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Survival Rate | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Arrhythmias, Cardiac; Case-Control Studies; Ciprofloxacin; Clarithromycin; Cohort Studies; Community Health Planning; Databases, Factual; Drug Monitoring; Erythromycin; Humans; Italy; Levofloxacin; Miocamycin; Norfloxacin; Ofloxacin; Pharmacoepidemiology; Risk Factors | 2005 |
Spectrophotometric determination of some fluoroquinolone antibacterials by binary complex formation with xanthene dyes.
Topics: Anti-Infective Agents; Ciprofloxacin; Eosine Yellowish-(YS); Levofloxacin; Merbromin; Norfloxacin; Ofloxacin; Spectrophotometry, Ultraviolet; Tablets | 2004 |
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pneumococcal Infections; Population Surveillance; Serotyping; Streptococcus pneumoniae; Time Factors; United States | 2005 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2005 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia | 2005 |
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Streptococcus pneumoniae; Time Factors | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa | 2005 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain.
Topics: Amino Acid Substitution; Anti-Infective Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Carrier Proteins; Ciprofloxacin; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Molecular Epidemiology; Molecular Sequence Data; Ofloxacin; Spain; Streptococcal Infections; Streptococcus pyogenes | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantation; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Rabbits | 2005 |
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Drug Synergism; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Tuberculosis | 2005 |
Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro.
Topics: Anti-Infective Agents; Ciprofloxacin; Female; Fetus; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Ofloxacin; Placenta; Pregnancy; Pregnancy Complications, Infectious | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Point Mutation; Quinolines; Sequence Analysis, DNA | 2005 |
Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia.
Topics: Adult; Ciprofloxacin; Cyclosporine; Humans; Levofloxacin; Male; Ofloxacin; Red-Cell Aplasia, Pure | 2005 |
A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Ceftriaxone; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Product Surveillance, Postmarketing; Retrospective Studies | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Fluoroquinolones; Fosfomycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones | 2005 |
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Urinary Tract Infections | 2005 |
Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; DNA, Bacterial; Evaluation Studies as Topic; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2006 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa | 2006 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Levofloxacin; Long QT Syndrome; Male; Ofloxacin; Prognosis; Prospective Studies; Prostatitis; Respiratory Tract Infections; Severity of Illness Index; Urinary Tract Infections | 2006 |
Comparative study of antimicrobial release kinetics from polymethylmethacrylate.
Topics: Acetamides; Anti-Bacterial Agents; Area Under Curve; Cefazolin; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Polymethyl Methacrylate; Rifampin | 2006 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Levofloxacin; Male; Ofloxacin; Prostate-Specific Antigen; Prostatitis | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluoroquinolones; Formularies as Topic; Gatifloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Methicillin; Methicillin Resistance; Ofloxacin; Pseudomonas aeruginosa; Regression Analysis; Retrospective Studies; Staphylococcus aureus | 2006 |
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Levofloxacin; Male; Middle Aged; Ofloxacin; Pseudomonas Infections; Quinolones; Regression Analysis; Retrospective Studies; Risk Factors | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Quinolones sensitize gram-negative bacteria to antimicrobial peptides.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Cell Membrane Permeability; Ciprofloxacin; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2006 |
Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain.
Topics: Alleles; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance; Erythromycin; Genes, Bacterial; Genetic Variation; Hospitals; Humans; Levofloxacin; Medical Records; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Ofloxacin; Pneumococcal Infections; Retrospective Studies; Spain; Species Specificity; Streptococcus pyogenes; Superantigens; Tetracycline; Urban Population | 2006 |
Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A; Salmonella typhi | 2007 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
[Bilophila wadsworthia isolated from surgical specimens].
Topics: Anti-Bacterial Agents; beta-Lactams; Bilophila; Ciprofloxacin; Clindamycin; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Humans; Japan; Levofloxacin; Minocycline; Ofloxacin; Peritonitis; Postoperative Complications; Specimen Handling; Surgical Wound Infection | 2006 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hemolysin Proteins; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Ultraviolet Rays; Urinary Tract Infections | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones.
Topics: Antigens, Polyomavirus Transforming; Antiviral Agents; Cell Line, Tumor; Ciprofloxacin; Cytopathogenic Effect, Viral; DNA Helicases; DNA Replication; DNA, Viral; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Reproducibility of Results; Simian virus 40; Time Factors; Viral Plaque Assay; Virus Replication | 2007 |
Multidrug-induced erythema multiforme.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Ceftriaxone; Ciprofloxacin; Drug Hypersensitivity; Erythema Multiforme; Female; Humans; Levofloxacin; Methenamine; Ofloxacin; Piroxicam; Skin Tests; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2007 |
Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Cell Count; Cell Survival; Cells, Cultured; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Epithelium, Corneal; Fluoroquinolones; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Quinolines; Serratia marcescens; Staphylococcus aureus | 2007 |
[Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Moraxella catarrhalis; Naphthyridines; Ofloxacin; Pseudomonas aeruginosa; Respiratory Tract Infections; Streptococcus | 2007 |
An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Monte Carlo Method; Ofloxacin; Pseudomonas aeruginosa | 2007 |
[Fluoroquinolone-induced tendon diseases].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Female; Humans; Levofloxacin; Magnetic Resonance Imaging; Male; Middle Aged; Ofloxacin; Rupture; Tendinopathy; Ultrasonography | 2007 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Escherichia coli; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostatitis | 2008 |
Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Chryseobacterium; Ciprofloxacin; Female; Flavobacteriaceae Infections; Humans; Infant; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome | 2008 |
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Female; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Porins | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
[Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Eye; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2008 |
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, Bacterial; Emergencies; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pyelonephritis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2008 |
Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2008 |
Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1.
Topics: Anti-Bacterial Agents; Biological Transport; Cell Line, Tumor; Ciprofloxacin; Glucose; Glucose Transporter Type 1; Humans; Levofloxacin; Ofloxacin; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspergillus fumigatus; Aza Compounds; Candida albicans; Ciprofloxacin; Drug Antagonism; Drug Synergism; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella melitensis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Norfloxacin; Ofloxacin; Quinolines; Sequence Analysis, DNA | 2009 |
[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].
Topics: Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin | 2009 |
Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Topics: Anti-Infective Agents; Argentina; Biofilms; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Stenotrophomonas maltophilia | 2009 |
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Community-Acquired Infections; DNA Gyrase; DNA Mutational Analysis; DNA Transposable Elements; Fluoroquinolones; Gene Expression Profiling; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Ofloxacin; Penicillin-Binding Proteins; Selection, Genetic; SOS Response, Genetics; Staphylococcal Infections; Transcription Factors; Up-Regulation | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Neisseria gonorrhoeae; Ofloxacin; Quinolines; Selection, Genetic | 2009 |
Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cross Infection; Drug Synergism; Drug Therapy, Combination; Ertapenem; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2008 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Outpatients; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Rhinitis; Sinusitis; Surgical Wound Infection | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cephalosporins; Cetuximab; Ciprofloxacin; ErbB Receptors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Ofloxacin; Paronychia; Retrospective Studies; Skin | 2010 |
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan | 2010 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Klebsiella; Klebsiella Infections; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Respiratory Tract Infections; Selection, Genetic; Urinary Tract Infections | 2010 |
Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Stability; Fluoroquinolones; Humans; Least-Squares Analysis; Levofloxacin; Ofloxacin; Oxazines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2010 |
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Bacterial; Eye Infections, Bacterial; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Vancomycin | 2010 |
A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
Topics: Anti-Bacterial Agents; Canada; Ciprofloxacin; Drug Utilization; Fluoroquinolones; Humans; Influenza, Human; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Risk Factors; Socioeconomic Factors | 2010 |
Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma.
Topics: Anti-Infective Agents; Chromatography, Liquid; Ciprofloxacin; Drug Stability; Fluoroquinolones; Humans; Levofloxacin; Linear Models; Norfloxacin; Ofloxacin; Reproducibility of Results; Sensitivity and Specificity | 2011 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cohort Studies; Drug Resistance, Bacterial; Escherichia coli; Feces; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Nasal Cavity; Ofloxacin; Pharynx; Prospective Studies; Risk Factors; Staphylococcus; Streptococcus; Young Adult | 2010 |
Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Compounding; Drug Delivery Systems; Drug Stability; Lactic Acid; Levofloxacin; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Ofloxacin; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Solubility; Surface-Active Agents; Vitamin E; Water | 2011 |
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Cricetinae; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mesocricetus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prohibitins; Quinolines | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2011 |
[Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Lethal Dose 50; Levofloxacin; Mice; Models, Animal; Nalidixic Acid; Ofloxacin; Plague; Virulence; Yersinia pestis | 2010 |
Fluoroquinolones influence the intracellular calcium handling in individuals susceptible to malignant hyperthermia.
Topics: Animals; Calcium; Ciprofloxacin; Disease Susceptibility; Fluoroquinolones; Levofloxacin; Malignant Hyperthermia; Muscle Contraction; Muscle, Skeletal; Nucleic Acid Synthesis Inhibitors; Ofloxacin; Swine | 2011 |
Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases.
Topics: Anti-Bacterial Agents; Aza Compounds; Calixarenes; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Indicators and Reagents; Ions; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Solutions | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Prostatitis; Young Adult | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
Prevalence of plasmid-mediated quinolone resistance determinants in Citrobacter freundii isolates from Anhui province, PR China.
Topics: China; Ciprofloxacin; Citrobacter freundii; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Ofloxacin; Plasmids | 2011 |
Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dipeptides; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Membrane Transport Proteins; Microbial Sensitivity Tests; Ofloxacin; Piperazine; Piperazines; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |
Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Delivery Systems; Implants, Experimental; Levofloxacin; Linear Models; Ofloxacin; Rabbits; Tandem Mass Spectrometry; Vitreous Body | 2012 |
Critical appraisal of air pouch infection model in rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Exudates and Transudates; Female; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rats; Rats, Wistar; Staphylococcus aureus; Vancomycin | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; Lung Diseases; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gallbladder Diseases; Hospitalization; Humans; Levofloxacin; Liver Diseases; Microbial Sensitivity Tests; Ofloxacin; Population Surveillance; Practice Guidelines as Topic; Prevalence; Prospective Studies; Pseudomonas aeruginosa; Taiwan; Time Factors | 2012 |
Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts.
Topics: Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2012 |
Evidence of in vivo prophage induction during Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA, Viral; Feces; Fluoroquinolones; Genetic Variation; Genome, Viral; Humans; Levofloxacin; Lysogeny; Microbial Sensitivity Tests; Mitomycin; Molecular Sequence Data; Moxifloxacin; Myoviridae; Ofloxacin; Prophages; Quinolines; Sequence Analysis, DNA; Virus Activation | 2012 |
Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Ciprofloxacin; Gene Expression; Genes, MDR; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Membrane Transport Proteins; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Stenotrophomonas maltophilia; Tetracycline | 2013 |
Phenotypic and molecular antibiotic resistance profile of Enterococcus faecalis and Enterococcus faecium isolated from different traditional fermented foods.
Topics: Ampicillin; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Enterococcus faecalis; Enterococcus faecium; Erythromycin; Fermentation; Food Contamination; Food Microbiology; Genes, Bacterial; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Nitrofurantoin; Ofloxacin; Penicillins; Phenotype; Vancomycin | 2013 |
Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Escherichia coli; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin | 2013 |
Interactions between new quinolone antibacterials and diagnostic drug containing manganese.
Topics: Algorithms; Anti-Bacterial Agents; Chelating Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Interactions; Levofloxacin; Manganese Compounds; Ofloxacin; Quinolones | 2013 |
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Mutant Proteins; Pneumonia, Bacterial; Treatment Outcome | 2013 |
Synthesis, in vitro antimycobacterial and antibacterial evaluation of IMB-070593 derivatives containing a substituted benzyloxime moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Gram-Negative Bacteria; Levofloxacin; Magnetic Resonance Spectroscopy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Oximes; Piperidines; Staphylococcus aureus | 2013 |
Prevalence and characterization of plasmid-mediated quinolone resistance genes in Salmonella isolated from poultry in Korea.
Topics: Animals; Blotting, Southern; Ciprofloxacin; DNA Primers; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Gene Transfer, Horizontal; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Plasmids; Polymerase Chain Reaction; Poultry; Poultry Diseases; Quinolones; Republic of Korea; Salmonella; Salmonella Infections, Animal | 2013 |
Effect of subinhibitory concentrations of fluoroquinolones on biofilm production by clinical isolates of Streptococcus pyogenes.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Microscopy, Confocal; Microscopy, Electron, Scanning; Norfloxacin; Ofloxacin; Streptococcal Infections; Streptococcus pyogenes; Virulence | 2013 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cohort Studies; Diabetes Complications; Female; Fluoroquinolones; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Moxifloxacin; Odds Ratio; Propensity Score; Quinolines; Taiwan | 2013 |
US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Female; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Male; Middle Aged; Moxifloxacin; Quinolines; United States | 2013 |
Environmental photochemistry of fluoroquinolones in soil and in aqueous soil suspensions under solar light.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Photolysis; Soil; Soil Pollutants; Sunlight; Suspensions; Water | 2014 |
[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Myasthenia Gravis; Quinolines; Retrospective Studies; Young Adult | 2013 |
Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carrier Proteins; Ciprofloxacin; Dipeptides; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Levofloxacin; Membrane Transport Modulators; Microbial Sensitivity Tests; Piperacillin; Pyrans; Pyridines | 2014 |
Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacteremia; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Neutropenia; Retrospective Studies; Young Adult | 2013 |
Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Hydrogen-Ion Concentration; Levofloxacin; Microbial Sensitivity Tests; Quinolones | 2014 |
Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Staphylococcal Infections; Staphylococcus epidermidis; United States | 2014 |
Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Comorbidity; Data Interpretation, Statistical; Databases, Factual; Female; Fluoroquinolones; Hospitals, Veterans; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Patient Safety; Quinolines; Retrospective Studies; Risk Factors; Socioeconomic Factors; United States; United States Department of Veterans Affairs | 2014 |
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Aza Compounds; Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluoroquinolones; Indoles; Injections, Intravenous; Levofloxacin; Male; Models, Animal; Moxifloxacin; Polypharmacy; Protein Kinase Inhibitors; Pyrroles; Quinolines; Rabbits; Spectrophotometry, Ultraviolet; Sunitinib | 2013 |
[Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Pneumococcal Infections; Polymerase Chain Reaction; Streptococcus pneumoniae; Young Adult | 2013 |
Environmental impact assessment of pharmaceutical prescriptions: Does location matter?
Topics: Agriculture; Anti-Bacterial Agents; Ciprofloxacin; Environment; Environmental Monitoring; Europe; Humans; Levofloxacin; Sewage; Water Pollutants, Chemical | 2014 |
Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Enterohepatic Circulation; Glucuronidase; Glucuronides; Immunosuppressive Agents; In Vitro Techniques; Inhibitory Concentration 50; Levofloxacin; Mycophenolic Acid; Ofloxacin; Phenolphthaleins; Time Factors | 2014 |
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Eye Infections, Bacterial; Gentamicins; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2014 |
Molecular analysis of low-level fluoroquinolone resistance in clinical isolates of Moraxella catarrhalis.
Topics: Adult; Amino Acid Sequence; Child; Ciprofloxacin; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Moraxella catarrhalis | 2014 |
The effect of some fluoroquinolone family members on biospeciation of copper(II), nickel(II) and zinc(II) ions in human plasma.
Topics: Ciprofloxacin; Coordination Complexes; Copper; Fluoroquinolones; Humans; Ions; Levofloxacin; Moxifloxacin; Nickel; Ofloxacin; Zinc | 2014 |
Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Interactions; Drug Prescriptions; Female; Glipizide; Glyburide; Health Care Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Levofloxacin; Logistic Models; Male; Medicare; Metronidazole; Morbidity; Odds Ratio; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Texas; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2014 |
In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Quinolones; Selection, Genetic; Sequence Analysis, DNA | 2015 |
Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Mutation; Oxazines | 2015 |
Performance of Etest and disk diffusion for detection of ciprofloxacin and levofloxacin resistance in Salmonella enterica.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Humans; Levofloxacin; Salmonella enterica; Salmonella Infections | 2015 |
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genetic Variation; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Nalidixic Acid; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Sequence Analysis, DNA | 2015 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Microbial keratitis in los angeles: the doheny eye institute and the los angeles county hospital experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Child; Ciprofloxacin; Corneal Ulcer; Eye Infections, Bacterial; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitals, County; Humans; Levofloxacin; Los Angeles; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies | 2015 |
Microbiological and clinical features of four cases of catheter-related infection by Methylobacterium radiotolerans.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Catheter-Related Infections; Child; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Methylobacterium; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2015 |
For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Fluoroquinolones; Humans; Image-Guided Biopsy; Levofloxacin; Male; Middle Aged; Postoperative Complications; Prostate; Retrospective Studies; Severity of Illness Index; Ultrasonography, Interventional | 2015 |
Editorial Comment.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Male; Postoperative Complications; Prostate | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
Sunlight-induced degradation of fluoroquinolones in wastewater effluent: Photoproducts identification and toxicity.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Environmental Monitoring; Fluoroquinolones; Levofloxacin; Photolysis; Spectrometry, Mass, Electrospray Ionization; Sunlight; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2015 |
Fluoroquinolone-based antimicrobial prophylaxis in patients undergoing transrectal ultrasound-guided prostate biopsy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Humans; Image-Guided Biopsy; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Prostate; Prostatic Neoplasms; Ultrasonography | 2015 |
Trends of fluoroquinolone-resistant Escherichia coli amongst urinary isolates in children: a 10 year surveillance study.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Epidemiological Monitoring; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Microbial Sensitivity Tests; Urinary Tract Infections | 2015 |
Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Emergency Service, Hospital; Escherichia coli; Escherichia coli Infections; Female; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2015 |
Development of a Pefloxacin Disk Diffusion Method for Detection of Fluoroquinolone-Resistant Salmonella enterica.
Topics: Anti-Bacterial Agents; Bacteremia; Base Sequence; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Nalidixic Acid; Ofloxacin; Pefloxacin; Salmonella enterica; Salmonella Infections; Sequence Analysis, DNA | 2015 |
Evaluation of Surrogate Disk Tests for Detection of Ciprofloxacin and Levofloxacin Resistance in Clinical Isolates of Salmonella enterica.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Salmonella enterica | 2015 |
Molecularly imprinted polymers for the solid-phase extraction of four fluoroquilones from milk and lake water samples.
Topics: Animals; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Gatifloxacin; Lakes; Levofloxacin; Milk; Molecular Imprinting; Polymethyl Methacrylate; Solid Phase Extraction; Water Pollutants, Chemical | 2015 |
Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic Fibrosis; Humans; Levofloxacin; Limit of Detection; Solid Phase Microextraction; Sputum | 2015 |
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013.
Topics: Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Bacterial; England; Epidemiological Monitoring; Fluoroquinolones; Gentamicins; Humans; Infant; Infant, Newborn; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tetracycline; Ureaplasma; Ureaplasma Infections; Wales | 2016 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult | 2016 |
Green foot ulcers.
Topics: Acetic Acid; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Dermoscopy; Female; Fluorescence; Foot Ulcer; Humans; Immersion; Levofloxacin; Middle Aged; Pigments, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
[The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Bacteriuria; Cefuroxime; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Escherichia coli Infections; European Union; Gentamicins; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Reference Standards; Sulbactam; Trimethoprim, Sulfamethoxazole Drug Combination; Turkey; Urinary Tract Infections; Uropathogenic Escherichia coli | 2015 |
Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin.
Topics: Adolescent; Amoxicillin; Anaphylaxis; Ciprofloxacin; Clarithromycin; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Levofloxacin; Male; Tonsillitis | 2016 |
Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Pulmonary Disease, Chronic Obstructive | 2016 |
[Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluorometry; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Humans; Indicator Dilution Techniques; Levofloxacin; Microbial Sensitivity Tests; Mutation | 2016 |
Re: For Single Dosing, Levofloxacin is Superior to Ciprofloxacin when Combined with an Aminoglycoside in Preventing Severe Infections after Prostate Biopsy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Ciprofloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Prostate | 2016 |
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Inhibitory Concentration 50; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2016 |
Increasing resistance to fluoroquinolones among Haemophilus species in Southern Taiwan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Haemophilus influenzae; Haemophilus parainfluenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Taiwan | 2017 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
The Emergence of Quinolone Resistant Shigella sonnei, Pondicherry, India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Bacterial; Dysentery, Bacillary; Feces; Humans; India; Levofloxacin; Microbial Sensitivity Tests; Plasmids; Quinolones; Shigella sonnei | 2016 |
Drug Susceptibility Assessment in Stenotrophomonas Maltophilia Strains Isolated From the Blood of Organ Transplantation Recipients in a Warsaw Teaching Hospital During 2011 to 2014.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clavulanic Acids; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Levofloxacin; Microbial Sensitivity Tests; Organ Transplantation; Stenotrophomonas maltophilia; Ticarcillin; Transplant Recipients; Trimethoprim, Sulfamethoxazole Drug Combination | 2016 |
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
Topics: 1-Methyl-4-phenylpyridinium; Aminosalicylic Acid; Animals; Antitubercular Agents; Ciprofloxacin; HEK293 Cells; Humans; Inhibitory Concentration 50; Ion Transport; Kinetics; Levofloxacin; Linezolid; Metformin; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyrazinamide; Rifabutin; Rifampin; Zidovudine | 2016 |
Robust HPLC-MS/MS method for levofloxacin and ciprofloxacin determination in human prostate tissue.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Limit of Detection; Male; Prostate; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Temperature | 2017 |
Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Topics: Acne Vulgaris; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Propionibacterium acnes; Quinolizines | 2016 |
Plasmid-mediated quinolone resistance determinants among Gram-negative bacteraemia isolates: a hidden threat.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Gram-Negative Bacterial Infections; Greece; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Quinolones; R Factors; Stenotrophomonas maltophilia | 2017 |
Assessment of antibiotic resistance in Klebsiella pneumoniae exposed to sequential in vitro antibiotic treatments.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests | 2016 |
5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
Topics: Administration, Intravenous; Administration, Oral; Adult; Ambulatory Care; Ciprofloxacin; Escherichia coli; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sex Factors; Time Factors; Urinary Tract Infections | 2016 |
Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blood; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections; Urine | 2017 |
Comparison of UTI antibiograms stratified by ED patient disposition.
Topics: Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, Bacterial; Emergency Service, Hospital; Escherichia coli; Escherichia coli Infections; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Nitrofurantoin; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Urinary Tract Infections | 2017 |
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Topics: Administration, Inhalation; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Deoxyribonuclease I; Dry Powder Inhalers; Expectorants; Humans; Levofloxacin; Microscopy, Electron, Scanning; Particle Size; Powders; Recombinant Proteins; Spectroscopy, Fourier Transform Infrared | 2017 |
Cardiotoxic effect of levofloxacin and ciprofloxacin in rats with/without acute myocardial infarction: Impact on cardiac rhythm and cardiac expression of Kv4.3, Kv1.2 and Nav1.5 channels.
Topics: Animals; Anti-Bacterial Agents; Cardiotoxins; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; Gene Expression; Heart Rate; Kv1.2 Potassium Channel; Levofloxacin; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Rats; Rats, Wistar; Shal Potassium Channels | 2017 |
Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Moxifloxacin; Neutropenia; Randomized Controlled Trials as Topic; Retrospective Studies | 2017 |
Deficiency of quorum sensing system inhibits the resistance selection of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin in vitro.
Topics: Bacterial Proteins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Levofloxacin; Ligases; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Trans-Activators; Transcription Factors; Virulence Factors | 2017 |
Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Developing Countries; Diarrhea; Dysentery; Humans; Levofloxacin; Military Personnel; Rifamycins; Rifaximin | 2017 |
Evaluation of lytic bacteriophages for control of multidrug-resistant Salmonella Typhimurium.
Topics: Anti-Bacterial Agents; Bacteriophages; Biological Control Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Host-Pathogen Interactions; Hot Temperature; Hydrogen-Ion Concentration; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Norfloxacin; Salmonella typhimurium; Tetracycline | 2017 |
Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Levofloxacin; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies | 2018 |
Sub-inhibitory concentrations of fluoroquinolones increase conjugation frequency.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Conjugation, Genetic; Drug Resistance, Bacterial; Escherichia coli; Exome Sequencing; Fluoroquinolones; Gene Expression Regulation, Bacterial; Gene Transfer, Horizontal; Levofloxacin; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; SOS Response, Genetics; Transcriptome; Virulence Factors | 2018 |
Association between oral fluoroquinolone use and lateral canthal tendon rupture: case report.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Blepharoplasty; Ciprofloxacin; Conjunctival Diseases; Drug Therapy, Combination; Ectropion; Female; Humans; Levofloxacin; Pneumonia, Bacterial; Rupture; Suture Techniques; Tendon Injuries | 2018 |
Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quinolones; Structure-Activity Relationship | 2018 |
Graphene oxide-facilitated transport of levofloxacin and ciprofloxacin in saturated and unsaturated porous media.
Topics: Adsorption; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Graphite; Levofloxacin; Porosity | 2018 |
Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Corneal Ulcer; Eye Infections, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Polymyxin B; Retrospective Studies; Risk Factors; Stenotrophomonas maltophilia; Tobramycin; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2018 |
Upconversion particle@Fe
Topics: Animals; Biosensing Techniques; Ciprofloxacin; Enoxacin; Enrofloxacin; Erbium; Fishes; Fleroxacin; Fluorescent Dyes; Fluorides; Fluoroquinolones; Levofloxacin; Magnetite Nanoparticles; Molecular Imprinting; Quinolones; Reproducibility of Results; Seafood; Ytterbium; Yttrium | 2018 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2018 |
Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome | 2018 |
When antibiotics turn toxic.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Antioxidants; Ciprofloxacin; Female; Fluoroquinolones; Genetic Testing; Humans; Inactivation, Metabolic; Levofloxacin; Male; Mice; Mitochondria; Naphthyridines; Ofloxacin; Oxidative Stress; Syndrome; Topoisomerase II Inhibitors; United States; United States Food and Drug Administration | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Ciprofloxacin; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Combinations; Imipenem; Levofloxacin; Linezolid; Meningitis, Bacterial; Meropenem; Rabbits; Treatment Failure | 2018 |
Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Italy; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers | 2018 |
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey | 2018 |
Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Female; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Middle Aged; Retrospective Studies; Young Adult | 2019 |
Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cefixime; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Heart Arrest; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Protective Factors; Republic of Korea; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation; Ventricular Flutter | 2018 |
AmpC beta-lactamases in Klebsiella pneumoniae: An emerging threat to the paediatric patients.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefoperazone; Cefoxitin; Cephalosporins; Child; Child, Preschool; Ciprofloxacin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals, Pediatric; Humans; Imipenem; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Pakistan; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2018 |
Replicon typing of plasmids in environmental Achromobacter sp. producing quinolone-resistant determinants.
Topics: Achromobacter; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Typing Techniques; Brazil; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Norfloxacin; Plasmids; Replicon; Soil Microbiology; Water Microbiology | 2018 |
Anaphylactic shock secondary to oral ofloxacin administration with cross-reactivity to levofloxacin and ciprofloxacin.
Topics: Administration, Oral; Adolescent; Anaphylaxis; Ciprofloxacin; Cross Reactions; Drug Hypersensitivity; Escherichia coli Infections; Female; Humans; Levofloxacin; Ofloxacin; Skin Tests; Urinary Tract Infections | 2018 |
Simultaneous determination of levofloxacin and ciprofloxacin in human urine by ionic-liquid-based, dual-template molecularly imprinted coated graphene oxide monolithic solid-phase extraction.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Graphite; Healthy Volunteers; Humans; Levofloxacin; Molecular Imprinting; Molecular Structure; Particle Size; Polymers; Solid Phase Extraction; Surface Properties | 2019 |
Comparative
Topics: Adult; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, Bacterial; Female; Fluoroquinolones; Ghana; Humans; In Vitro Techniques; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pilot Projects; Urinary Tract Infections; Young Adult | 2018 |
Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacteriaceae; Levofloxacin; Microbial Sensitivity Tests | 2019 |
Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamases; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Empirical Research; Enterobacteriaceae; Female; Gene Expression; Humans; Levofloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Retrospective Studies; Rifampin; Spine; Streptococcus; Vancomycin | 2019 |
Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report.
Topics: Aged; Anti-Bacterial Agents; Antibody Specificity; Antifungal Agents; Autoantibodies; Autoimmune Diseases; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Substitution; Drug Therapy, Combination; Factor V; Factor V Deficiency; Fluoroquinolones; Humans; Levofloxacin; Male; Meropenem; Micafungin; Partial Thromboplastin Time; Pneumonia; Prothrombin Time | 2019 |
The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Ciprofloxacin; Clostridium Infections; Cohort Studies; Drug Prescriptions; Drug Resistance, Bacterial; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Michigan; Moxifloxacin; Pneumonia; Retrospective Studies; Risk; Surveys and Questionnaires | 2019 |
Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aortic Aneurysm, Thoracic; Aortic Dissection; Bayes Theorem; Child; Child, Preschool; Ciprofloxacin; Data Mining; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pharmacovigilance; United States; United States Food and Drug Administration; Young Adult | 2019 |
Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Female; Gram-Negative Bacteria; Humans; Kaplan-Meier Estimate; Length of Stay; Levofloxacin; Male; Middle Aged; Retrospective Studies; Treatment Failure; Urinary Tract Infections | 2019 |
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studies; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Ofloxacin; Peripheral Nervous System Diseases; Risk Factors; Sex Factors; United Kingdom | 2019 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Cysteine auxotrophy drives reduced susceptibility to quinolones and paraquat by inducing the expression of efflux-pump systems and detoxifying enzymes in S. Typhimurium.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cysteine; Drug Resistance, Multiple, Bacterial; Gene Deletion; Gene Expression; Genes, Bacterial; Humans; Levofloxacin; Membrane Transport Proteins; Mutation; Nalidixic Acid; Paraquat; Quinolones; Reactive Oxygen Species; Salmonella typhimurium; Sulfur | 2019 |
Assessment of antibiotic resistance in bacteriophage-insensitive Klebsiella pneumoniae.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteriophages; beta-Lactamases; Cefotaxime; Cephalothin; Chloramphenicol; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Humans; Klebsiella pneumoniae; Levofloxacin; Phage Therapy; Quinolones | 2019 |
Antibiotic-Based Conjugates Containing Antimicrobial HLopt2 Peptide: Design, Synthesis, Antimicrobial and Cytotoxic Activities.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Ciprofloxacin; Drug Stability; Escherichia coli; Fluconazole; HEK293 Cells; Hep G2 Cells; Humans; Immunoconjugates; Lactoferrin; Levofloxacin; Male; Microbial Sensitivity Tests; Peptide Fragments; Staphylococcus aureus; Swine | 2019 |
DAV131A Protects Hamsters from Lethal
Topics: Administration, Oral; Adsorption; Animals; Anti-Bacterial Agents; Charcoal; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Dysbiosis; Fluoroquinolones; Gastrointestinal Microbiome; Levofloxacin; Male; Mesocricetus | 2019 |
Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Topics: Anti-Bacterial Agents; Awareness; Ciprofloxacin; Cystic Fibrosis; Health Occupations; Humans; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Topics: Administration, Ophthalmic; Administration, Oral; Adult; Aspergillosis; Aspergillus; Ciprofloxacin; Coinfection; Conjunctiva; Corynebacterium; Corynebacterium Infections; Dacryocystorhinostomy; Drug Therapy, Combination; Female; Humans; Intubation; Lacrimal Duct Obstruction; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ophthalmic Solutions; Prostheses and Implants; Retrospective Studies; Slit Lamp Microscopy; Voriconazole | 2020 |
Microbial etiology, susceptibility profile of postradiation nasopharyngeal necrosis patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Anti-Bacterial Agents; Candida albicans; Ciprofloxacin; Female; Gentamicins; Humans; Levofloxacin; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Necrosis; Pseudomonas aeruginosa; Radiation Injuries; Retrospective Studies; Staphylococcus aureus; Treatment Outcome | 2020 |
Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay.
Topics: Adolescent; Adult; Aged; Amikacin; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Ceftazidime; Ciprofloxacin; Febrile Neutropenia; Female; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Incidence; Levofloxacin; Male; Meropenem; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous; Uruguay; Young Adult | 2020 |
Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Monitoring; Female; Humans; Levofloxacin; Limit of Detection; Male; Middle Aged; Moxifloxacin; Plasma; Reproducibility of Results; Rifampin; Tandem Mass Spectrometry | 2020 |
Emerging coexistence of three PMQR genes on a multiple resistance plasmid with a new surrounding genetic structure of qnrS2 in E. coli in China.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Genome Size; Levofloxacin; Microbial Sensitivity Tests; Mutation; Plasmids; Whole Genome Sequencing | 2020 |
The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; China; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA Gyrase; Drug Resistance, Bacterial; Enterotoxins; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Moxifloxacin; Vancomycin | 2020 |
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and dru
Topics: Animals; Aortic Aneurysm; Ciprofloxacin; Dissection; Humans; Idiopathic Pulmonary Fibrosis; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Letter to the Editor: Consideration on "An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin- association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administra
Topics: Aortic Aneurysm; Ciprofloxacin; Dissection; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Ciprofloxacin; Disease Models, Animal; Levofloxacin; Plague; Yersinia pestis | 2020 |
Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Candida; Cell-Penetrating Peptides; Ciprofloxacin; Drug Resistance, Bacterial; HEK293 Cells; Hep G2 Cells; HL-60 Cells; Humans; Levofloxacin; Microbial Sensitivity Tests; Recombinant Fusion Proteins; Swine | 2020 |
Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa | 2020 |
Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Chlorpromazine; Ciprofloxacin; Cross Infection; Diclofenac; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Egypt; Fluoroquinolones; Humans; Levofloxacin; Propranolol | 2020 |
Water-soluble manganese porphyrins as good catalysts for cipro- and levofloxacin degradation: Solvent effect, degradation products and DFT insights.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Hydrogen Peroxide; Levofloxacin; Manganese; Porphyrins; Solvents; Water; Water Pollutants, Chemical | 2021 |
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line; Chlorocebus aethiops; Ciprofloxacin; Coronavirus Infections; COVID-19 Drug Treatment; Enoxacin; Fluoroquinolones; Humans; Levofloxacin; Middle East Respiratory Syndrome Coronavirus; Moxifloxacin; SARS-CoV-2; Vero Cells | 2020 |
Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Basophil Degranulation Test; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Quinolones; Skin Tests; Young Adult | 2021 |
Burden of enteral supplement interactions with common antimicrobial agents: a single-centre observational analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Calcium; Child; Child, Preschool; Ciprofloxacin; Doxycycline; Female; Humans; Infant; Iron; Levofloxacin; Male; Middle Aged; Retrospective Studies; Young Adult | 2022 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Hydrophilic deep eutectic solvents modified phenolic resin as tailored adsorbent for the extraction and determination of levofloxacin and ciprofloxacin from milk.
Topics: Adsorption; Animals; Anti-Bacterial Agents; Ciprofloxacin; Food Contamination; Formaldehyde; Hydrophobic and Hydrophilic Interactions; Levofloxacin; Milk; Phenols; Polymers; Solid Phase Extraction; Solvents | 2021 |
The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular
Topics: Anti-Infective Agents; Binding Sites; Ciprofloxacin; Computer Simulation; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Levofloxacin; Molecular Docking Simulation; Molecular Dynamics Simulation; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Viral Proteins | 2021 |
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Ciprofloxacin; Connective Tissue Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Musculoskeletal Diseases; Myalgia; Norfloxacin; Ofloxacin; Pain; Risk Factors; Tendinopathy; Tendons; Young Adult | 2021 |
Antibacterial efficacy of silver nanoparticles against metallo-β-lactamase (blaNDM, blaVIM, blaOXA) producing clinically isolated Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Metal Nanoparticles; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Silver | 2021 |
New chemiluminescent method of levofloxacin and ofloxacin determination based on terbium (III)-sensitized fluoroquinolone-KBrO
Topics: Ciprofloxacin; Fluoroquinolones; Levofloxacin; Norfloxacin; Terbium | 2021 |
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Coxiella burnetii; Doxycycline; Levofloxacin; Mice; Q Fever; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones.
Topics: Anaphylaxis; Anti-Bacterial Agents; Atracurium; Calcium Signaling; Cell Degranulation; Cells, Cultured; Ciprofloxacin; Drug Hypersensitivity; Humans; Immunoglobulin E; Levofloxacin; Mast Cells; Nerve Tissue Proteins; Neuromuscular Nondepolarizing Agents; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Rocuronium; Time Factors | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
The spectrophotometric determination of lipophilicity and dissociation constants of ciprofloxacin and levofloxacin.
Topics: 1-Octanol; Ciprofloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Permeability; Solubility; Water | 2022 |
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues.
Topics: Adenosine Deaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Ciprofloxacin; COVID-19; Creatinine; Fluoroquinolones; Glucose; Glutathione; Glutathione Peroxidase; Levofloxacin; Lipid Peroxidation; Malondialdehyde; Moxifloxacin; Nalidixic Acid; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; SARS-CoV-2; Superoxide Dismutase; Triglycerides | 2022 |
Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Culture Techniques, Three Dimensional; Cell Cycle; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Levofloxacin; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urogenital Neoplasms | 2021 |
Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Wisconsin | 2022 |
Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Retrospective Studies; Urinary Tract Infections | 2022 |
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Oxidative Stress; Stenotrophomonas maltophilia | 2022 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections.
Topics: Ampicillin; Anti-Bacterial Agents; Aztreonam; Cefepime; Ceftazidime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Infections; Gentamicins; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Prevalence; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Death, Sudden, Cardiac; Female; Fluoroquinolones; Humans; Hypoglycemia; Levofloxacin; Norfloxacin; Ontario; Renal Dialysis; Renal Insufficiency, Chronic; Retinal Detachment; Sepsis | 2022 |
Acinetobacter baumannii, Klebsiella pneumoniae and Elizabethkingia miricola isolated from wastewater have biodegradable activity against fluoroquinolone.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Flavobacteriaceae; Fluoroquinolones; Klebsiella pneumoniae; Levofloxacin; Sewage; Wastewater | 2022 |
Assessment of nationally recommended antibiotics for treatment of UTI in U.S.-Mexico border emergency departments.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefdinir; Cefuroxime; Cephalexin; Ciprofloxacin; Emergency Service, Hospital; Fluoroquinolones; Humans; Levofloxacin; Mexico; Nitrofurantoin; Retrospective Studies; Tetracyclines; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Urinary Tract Infections | 2022 |
Analysis of virulence genes, drug resistance detection, and pathogenicity in Enterococcus from farm animals.
Topics: Animals; Animals, Domestic; Anti-Bacterial Agents; Cattle; Cefotaxime; Chickens; Ciprofloxacin; Dogs; Drug Resistance; Drug Resistance, Bacterial; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gram-Positive Bacterial Infections; Levofloxacin; Mice; Microbial Sensitivity Tests; Sulfamethoxazole; Swine; Vancomycin; Virulence; Virulence Factors | 2022 |
Right hip gonococcal septic arthritis treatment with successful transition to oral fluoroquinolone.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Levofloxacin; Tetracycline | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Correlation between antibiotic consumption and resistance of Pseudomonas aeruginosa in a teaching hospital implementing an antimicrobial stewardship program: A longitudinal observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Stewardship; Ciprofloxacin; Hospitals, Teaching; Humans; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
The Medium Composition Impacts
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Osteomyelitis; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2022 |
Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
Topics: Amino Acids; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Quinolones; Salmonella; Salmonella enterica; Salmonella typhi; Typhoid Fever | 2022 |
Human health risk estimation of antibiotics transferred from wastewater and soil to crops.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Crops, Agricultural; Ecosystem; Humans; Lactuca; Levofloxacin; Soil; Soil Pollutants; Wastewater | 2023 |
The Combination of Salmonella Phage ST-3 and Antibiotics to Prevent Salmonella Typhimurium In Vitro.
Topics: Anti-Bacterial Agents; Bacteriophages; Ciprofloxacin; Levofloxacin; Myoviridae; Salmonella Phages; Salmonella typhimurium; Wastewater | 2022 |
A preventable, life-altering case of fluoroquinolone-associated tendonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Tendinopathy; Urinary Tract Infections | 2022 |
Genotypic Detection of
Topics: Agar; Amikacin; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Ciprofloxacin; Citrobacter koseri; Gentamicins; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections | 2022 |
Perioperative Antibiotic Prophylaxis in Radical Prostatectomy: "Single-Shot" versus Multiday Regimen.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Humans; Levofloxacin; Male; Prostatectomy; Retrospective Studies | 2023 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |
Seasonal distribution and dynamic evolution of antibiotics and evaluation of their resistance selection potential and ecotoxicological risk at a wastewater treatment plant in Jinan, China.
Topics: Anti-Bacterial Agents; China; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Metronidazole; Seasons; Sewage; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Water Purification | 2023 |
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Microbiological Spectrum and Antibiogram of Urinary Tract Infection in a Tertiary Care Center from the Kingdom of Bahrain.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bahrain; beta-Lactamases; Carbapenems; Ciprofloxacin; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Levofloxacin; Male; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Evaluation of Gene Expression of
Topics: Bacterial Proteins; Ciprofloxacin; Gene Expression; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Multidrug Resistance-Associated Proteins; RNA, Ribosomal, 16S; Staphylococcal Infections; Staphylococcus aureus | 2022 |
Antibiotic susceptibility pattern of Portuguese environmental Legionella isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Doxycycline; Fluoroquinolones; Humans; Legionella; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Portugal | 2023 |
In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2023 |
Magnetic Fe
Topics: Algorithms; Anti-Bacterial Agents; Ciprofloxacin; Levofloxacin; Magnetic Phenomena; Norfloxacin | 2023 |
Microbial keratitis and antibiotic sensitivity patterns: A retrospective analysis at a tertiary center in Central India.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Erythromycin; Eye Infections, Bacterial; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Retrospective Studies | 2023 |
Comparative study of the toxicity mechanisms of quinolone antibiotics on soybean seedlings: Insights from molecular docking and transcriptomic analysis.
Topics: Anti-Bacterial Agents; Antioxidants; Chlorophyll; Ciprofloxacin; Enrofloxacin; Glycine max; Levofloxacin; Molecular Docking Simulation; Photosynthesis; Seedlings; Transcriptome | 2023 |
Molecular characterization of multidrug-resistant non-typeable Haemophilus influenzae with high-level resistance to cefuroxime, levofloxacin, and trimethoprim-sulfamethoxazole.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Cefuroxime; Ciprofloxacin; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |
Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Topics: Case-Control Studies; Ciprofloxacin; Fluoroquinolones; Heart Valve Diseases; Humans; Levofloxacin; Moxifloxacin; Retrospective Studies | 2023 |
Usefulness of medicine screening tools in the frame of pharmaceutical post-marketing surveillance.
Topics: Ciprofloxacin; Counterfeit Drugs; Humans; Levofloxacin; Metronidazole; Product Surveillance, Postmarketing; Substandard Drugs | 2023 |
Spatial trends and ecotoxic risk assessment of selected pharmaceuticals in sediments from Lake Victoria, Uganda, East Africa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Ecosystem; Environmental Monitoring; Ibuprofen; Lakes; Levofloxacin; Metoprolol; Pharmaceutical Preparations; Risk Assessment; Uganda; Water Pollutants, Chemical | 2024 |
Ciprofloxacin-Induced Anaphylactic Reaction Followed by Negative Provocation Test in Response to Levofloxacin: A Case Report.
Topics: Anaphylaxis; Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin | 2023 |